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GENERAL INTRODUCTION AND OUTLINE OF THE THESIS
Introduction
Postpartum haemorrhage, in this thesis defined as blood loss above 1000mL within the 
first 24 hours after birth, remains a major cause of maternal morbidity and mortality with 
an incidence that seems to be increasing over the last decade1-8. Although risk factors 
are in many occasions known to be present during pregnancy and birth, postpartum 
haemorrhage frequently occurs unexpectedly9-11. Also, women with known risk factors 
for postpartum haemorrhage often do not bleed excessively following childbirth. It 
has therefore proven difficult to predict postpartum haemorrhage based on clinical 
peripartum risk factors9,12,13.  Since postpartum haemorrhage remains an event with 
potentially serious consequences, developing a reliable screening tool for identification 
of women at increased risk is of utmost importance. Thus far, the best results for prior 
assessment of bleeding risk come from structured approaches to history taking by means 
of bleeding assessment tools (BATs) resulting in a bleeding score, originally developed 
to determine the likelihood of the presence of a bleeding disorder (von Willebrand 
disease)14-16. These bleeding assessment tools might also be useful  to identify women 
with a high risk  to bleed excessively prior to  childbirth17.  
Another moment potentially providing relevant information with respect to  prediction 
and personalized prevention of a severe maternal outcome is  the first phase of  postpartum 
haemorrhage.  Are we at that time able to identify changes in coagulation parameters that 
are predictive for severe maternal outcome? Some have suggested that low fibrinogen 
concentration might be the earliest predictor of progression towards severe postpartum 
haemorrhage18,19,20.   In order to determine the optimal strategy to monitor coagulopathy 
during birth, it is crucial to know patterns of changes in coagulation parameters in relation 
to the phases of postpartum haemorrhage and identify which parameters show the earliest 
changes associated with risk of severe maternal outcomes. High volumes of clear fluids 
may also have detrimental effects on  coagulation parameters. International guidelines 
on management of postpartum haemorrhage elucidate the lack of quantitative evidence 
on the effect of different fluid management strategies on parameters of coagulopathy. To 
enable evidence-based recommendations on fluid management strategies in women with 
severe postpartum haemorrhage, more insight is needed on the changes of coagulation 
parameters after the administration of different volumes of fluids21. 
By close monitoring of haemostasis, abnormalities in coagulation parameters may be 
detected soon after their onset. This could contribute to more personalized haemostatic 
therapy for women experiencing postpartum haemorrhage, potentially leading to 
better maternal outcomes22.  Due to long turn-around times of traditional coagulation 
parameters like Clauss fibrinogen, their clinical applicability in presence of rapid bleeding is 
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method for haemostasis testing, like ROTEM® thromboelastometry. Selection of the right 
target population is very important when evaluating the therapeutic value of an applied 
intervention. A Clauss fibrinogen concentration of ≤2 g/L is often used as an indication 
for targeted haemostatic treatment18,23. When using thromboelastometry, a qualitative 
assessment of fibrinogen status is provided by the ROTEM® FIBTEM assay. The optimal 
ROTEM® FIBTEM A5 value corresponding to the cut-off point of a Clauss fibrinogen level of 
≤2 g/L has yet to be identified. Recently, the ROTEM® Sigma, a fully automated successor 
of the ROTEM® Delta device, was launched onto the market. The fact that this device lacks 
the pipetting procedure of its predecessor, makes it attractive as a point-of-care device to 
be used at a patient’s bedside. Since treatment flowcharts often use exact ROTEM® assay 
cut-off points, critical evaluation should be performed into the values provided by both 
the old and the new device to define potential consequences for daily clinical practice. 
As part of the management of postpartum haemorrhage, haemostatic agents may 
be administered to support coagulation and correct for acquired coagulopathy21,24. 
One of these agents is tranexamic acid, an antifibrinolytic agent25. In the WOMAN trial, 
administration of tranexamic acid in an early stage of postpartum haemorrhage was 
compared to placebo, showing a reduction of maternal mortality due to bleeding from 
1.9% to 1.5%26. However, since maternal mortality has become a rare event in high-
resource countries, it needs to be elucidated whether administration of tranexamic acid 
early during postpartum haemorrhage also has a positive effect on clinical outcome or 
amount of blood loss in a high-resource setting.
Aims and objectives
The main aim of the research described in this thesis was to improve prognostic and 
diagnostic strategies for major obstetric haemorrhage, which may subsequently lead to 
a reduction of severe maternal morbidity, mortality and need for surgical interventions.
In pursuit of this aim, the following objectives were stated:
1. To examine the predictive value of a bleeding assessment tool for postpartum 
haemorrhage.
2. To describe the change in coagulation parameters and the influence of fluid 
management on coagulopathy during the course of postpartum haemorrhage and 
to examine the predictive value of early changes of coagulation parameters for a 
severe maternal outcome.
3. To assess correlations between results obtained by thromboelastometry and 
traditional coagulation parameters in women experiencing postpartum haemorrhage 
and define cut-off points for detecting women in need of a haemostatic intervention.
In order to answer our research questions, two large multicentre cohort studies were 
performed. The Transfusion strategies in women during Major Obstetric Haemorrhage-1 
(TeMpoH-1) study was a nationwide retrospective cohort study in 61 hospitals in the 
Netherlands assessing 191.772 births between 2011 and 2013.  The TeMpOH-2 (Towards 
better Prognostic and Diagnostic strategies for Major Obstetric Haemorrhage) study, 
was a prospective cohort study in three hospitals in the Netherlands between February 
2015 and April 2018 assessing 17.203 births. A total of 1982 women experiencing (severe) 
postpartum haemorrhage were included in both studies. A part of the results of the 
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Outline of this thesis
The first part of this thesis focusses on prediction of postpartum haemorrhage. 
Chapter 2 contains results of a prospective evaluation of the predictive value 
of the TeMpOH-2 self-BAT derived from the condensed MCMDM-1VWD BAT for 
postpartum haemorrhage. To enable prediction of severe maternal outcome based 
on early changes in coagulation parameters, changes occurring during postpartum 
haemorrhage were explored. Chapter 3 describes coagulation parameters during the 
course of severe postpartum haemorrhage and compares coagulation parameters 
during early postpartum haemorrhage between women with and without adverse 
maternal outcome. The second part of this thesis focusses on improvement of 
diagnostic strategies for postpartum haemorrhage. Chapter 4 provides insight in real-
world changes in levels of coagulation parameters after administration of different 
volumes of clear fluids to women suffering from major postpartum haemorrhage. 
In Chapter 5 a comparison of thromboelastometry by the ROTEM® Delta versus the 
Sigma device is described. Chapter 6 contains the results of a comparison between 
results of thromboelastometry and traditional coagulation parameters, including 
Clauss fibrinogen. The optimal cut-off point for ROTEM® FIBTEM A5 is defined to 
detect women with a Clauss fibrinogen concentration ≤ 2g/L. Finally, in Chapter 7 the 
association between tranexamic acid administration at an early stage in the course of 
persistent postpartum haemorrhage and severe acute maternal morbidity and blood 
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BLEEDING SCORE TO PREDICT POSTPARTUM HAEMORRHAGE
Introduction
Postpartum haemorrhage continues to be a leading cause of maternal health problems 
worldwide1-4. Although risk factors are often known to be present during pregnancy and 
birth, postpartum haemorrhage frequently occurs unexpectedly5-7. Also, women with 
known risk factors for postpartum haemorrhage frequently do not bleed excessively 
following childbirth. It has therefore proven difficult to develop a reliable prediction 
model for postpartum haemorrhage based on clinical peripartum risk factors5,8,9. 
 
In general clinical practice, assessment of bleeding risk is performed by assessing 
clinical history, performing a physical examination and sometimes the use of screening 
coagulation tests10,11. However, coagulation testing to predict bleeding risk prior to 
invasive procedures was found to be not useful due to limited sensitivity and specificity 
of the tests and low prevalence of bleeding disorders12,13. The best results for prior 
assessment of bleeding risk come from more structured approaches to history taking 
by means of bleeding assessment tools (BATs), originally developed to determine the 
likelihood of the presence of a bleeding disorder (von Willebrand disease)14-16. In adults 
with von Willebrand disease, bleeding assessment tools have shown to be able to predict 
future bleeding events17.  Another very useful application of bleeding assessment tools 
would be the ability contribute to the identification of subjects who are more likely 
to bleed excessively prior to their exposure to invasive procedures, surgery and also 
childbirth18.  The main causes for postpartum haemorrhage are known to be obstetrical, 
but undiagnosed bleeding disorders can increase the risk of postpartum haemorrhage 
about threefold7,19. Since postpartum haemorrhage remains an event that could 
have serious consequences including severe acute maternal morbidity and mortality, 
it would be of great significance to have a reliable screening tool that could contribute 
to the identification of women with an increased risk of excessive blood loss prior to 
childbirth. 
The aim of this study was to examine the added predictive value of the TeMpOH-2 self-
BAT derived from the condensed MCMDM-1VWD (Molecular and Clinical Markers for the 




Background: A reliable screening tool that could contribute to the identification of 
women with an increased risk of postpartum haemorrhage would be of great clinical 
significance. 
Objectives: The aim of this study was to examine the added predictive value of a bleeding 
assessment tool for postpartum haemorrhage exceeding 1000mL.
Patients/Methods: Prospective two-centre cohort study among 1147 pregnant women 
visiting the outpatient clinic or the maternity ward who completed a bleeding assessment 
tool prior to birth. The condensed MCMDM-1VWD bleeding assessment tool was adjusted 
to a questionnaire that could be used as a self-assessment bleeding tool. A score of ≥ 4 
was considered to be abnormal.
Results: In the 1147 pregnant women in our cohort, bleeding scores ranged from -3 to 13, 
with a median of 1 (IQR -1 to 3); 197 (17%) women developed postpartum haemorrhage. 
Among women with a history of postpartum haemorrhage 29 percent developed 
postpartum haemorrhage. Among 147 women with an abnormal bleeding score (≥ 
4), 27 (18%) developed postpartum haemorrhage, whereas the remaining 170 cases 
of postpartum haemorrhage had a normal bleeding score. Despite the high incidence 
of postpartum haemorrhage, the ability of the bleeding score to predict postpartum 
haemorrhage was poor: area under Receiver Operating Curve 0.53 (95% CI 0.49 to 0.58) 
for PPH ≥ 1000mL. 
Conclusions: A history of significant postpartum haemorrhage was associated with 
an increased risk of subsequent postpartum haemorrhage. However, screening with 
a bleeding assessment tool did not help to discriminate women who will develop 
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Methods
Design and study population
We studied women who had been included in the TeMpOH-2 (Towards better Prognostic 
and Diagnostic strategies for Major Obstetric Haemorrhage) study, a prospective cohort of 
pregnant women in the Netherlands between February 2015 and April 2018. The women 
were recruited during their pregnancy at the outpatient clinics and maternity wards from 
two of the three participating hospitals, the Leiden University Medical Centre, in Leiden 
and the Isala Clinics in Zwolle. Included women were monitored for the occurrence of 
postpartum haemorrhage and followed until discharge from hospital after childbirth. 
At inclusion women were asked to complete a questionnaire containing a bleeding 
assessment tool. Answers to the questions of the bleeding assessment tool pertained 
to a woman’s pre-pregnancy condition. Postpartum haemorrhage was defined as any 
blood loss ≥1000 mL blood loss within 24 hours after childbirth. Blood loss ≥2000 mL 
was a secondary end point. To include as many women as possible, study information 
was provided by a trained nurse at a set third trimester consultation that was scheduled 
for all pregnant women visiting the outpatient clinic. Study information was also handed 
out to women during regular visits to the outpatient clinic. Moreover, women scheduled 
for caesarean section, were provided with study information on a second occasion 
during hospitalization prior to surgery, and  women admitted to the maternity ward 
overnight were visited by a research nurse in the morning and asked to participate in 
the study. For the present analysis we selected women from the TeMpOH-2 cohort for 
whom a completed bleeding assessment tool providing us with a valid bleeding score 
and data on volume of blood loss following childbirth were available. Women below 
18 years of age or a gestational age below 24 weeks at the time of birth were excluded. 
Known coagulation disorders or anticoagulant use were not exclusion criteria. Approval 
for the study was obtained by the Ethical Committee of the Leiden University Medical 
Centre (P13.246) and of the committee of the Isala Clinics. The study was registered at 
ClinicalTrials.gov (NCT02149472). Written informed consent was obtained from all 
participants. Bleeding assessment tools were completed by all women during pregnancy 
(always prior to childbirth) because of the possibility of recall bias when completing the 
bleeding assessment tool after birth. 
Bleeding assessment tool
We adjusted the condensed MCMDM-1VWD bleeding assessment tool to a written 
questionnaire that could be used as a self-assessment bleeding score. Medical terminology 
was converted into lay language and detail was added to items that needed extra 
explanation or examples that would otherwise be given by an expert (S1). The agreement 
between patient self-assessment and expert assessment of the bleeding symptoms was 
evaluated and found to be excellent: eight women participating in the study completed 
the TeMpOH-2 study self-BAT (without assistance) followed by the condensed MCMDM-
1VWD (administered by an expert). In both questionnaires, the same scoring key is 
applied. Scores were equal in seven of the eight participants, and a difference of +1 was 
found in one woman.
Calculation of  bleeding score
The questionnaire (derived from the condensed MCDM-1VWD BAT) comprised 
twelve areas of bleeding: epistaxis, cutaneous, bleeding from minor wounds, oral 
cavity, gastrointestinal bleeding, tooth extraction, surgery, menorrhagia, postpartum 
haemorrhage, muscle hematoma, hemarthrosis, central nervous system bleeding. The 
condensed MCDM-1VWD BAT as assessed in a primary care setting yielded a mean 
bleeding score in 100 healthy individuals of 0.16  with a range of normal bleeding scores 
from -3.2 to + 3.615. Accordingly, we considered a score of ≥ 4 as abnormal. 
Data collection
Participants completed the bleeding assessment tool either via a paper-based or web-
based questionnaire. Results of the paper-based questionnaire were scanned and 
evaluated by TeleForm®. TeleForm is a software application that enables the creation of 
forms for data collection and reads the returned data by use of a scanner. After processing 
and verifying of the data by a trained operator, data were exported from TeleForm into a 
SPSS database for further analyses. The web-based questionnaire was created in NetQ, an 
online questionnaire tool. Data were automatically exported to SPSS and then verified. 
Bleeding scores were calculated for all participants from the data derived from the 
bleeding assessment tool. Additional information was collected by well-trained research 
nurses who performed comprehensive chart reviews. Data were recorded from medical 
files available at the maternity ward for the following parameters: maternal age at the 
time of birth, parity, gestational age, mode of birth, presence of pre-eclampsia or HELLP 
syndrome, presence of a coagulation disorder, anticoagulant use and total volume of 
blood loss. Blood loss was measured by weighing gauzes and all other soaked materials 
and by the use of a collector bag and suction system in the operating theatre. In case 
women had experienced postpartum haemorrhage additional information was collected 
on cause of bleeding and treatment. 
Statistical analyses
Bleeding scores were calculated using the tool specific scoring key. Sensitivity, specificity, 
positive and negative predictive value and the area under the receiver operator curve 
(AUC’s) were calculated to quantify test characteristics of  the bleeding score in relation 
to the occurrence of  postpartum haemorrhage defined as more than 1000mL blood 
loss (primary endpoint) as well as more than 2000mL blood loss. Positive and negative 
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(epistaxis, cutaneous, bleeding from minor wounds, oral cavity, gastrointestinal bleeding, 
tooth extraction, surgery, menorrhagia, postpartum haemorrhage, muscle hematoma, 
hemarthrosis, central nervous system bleeding). To evaluate the possibility of selection 
bias due to a high number of women with caesarean sections, sensitivity analyses were 
performed excluding women who gave birth by elective caesarean section.    
Figure 1. Inclusion flowchart
Results
Patient characteristics
Over the three-year TeMpOH-2 inclusion period 1147 women for whom data were available 
on total volume of blood loss following childbirth, completed the bleeding assessment 
tool (Figure 1). Baseline characteristics are reported in Table 1. Women were on average 32 
years of age (IQR 29-35), gave birth at a median gestational age of 39.0 weeks (IQR 38.1-
40.3) and 30% delivered by caesarean section. In our cohort (197/1147)  17.2 % of women 
experienced postpartum haemorrhage ≥1000 mL and (55/1147) 4.8% of women lost 
more than 2000mL of blood following birth. Primary cause of postpartum haemorrhage 
was uterine atony or retained placenta in 68% of women and 25% of bleeds were the 
result of a surgical cause. Bleeding scores ranged from -3 to 13, with a median of 1 (IQR 
-1 to 3). Of the women in our cohort, (147/1147) 12.8% had an abnormal bleeding score 
of ≥ 4. The distribution of bleeding scores plotted to categories of increasing volume of 
blood loss is shown in Figure 2. The bubble plot displays number of women per bleeding 
score categorized in increasing volumes of blood loss. Larger bubbles represent a higher 
patient count. 
Discriminative ability of the bleeding score
The ability of the score to discriminate women with postpartum haemorrhage ≥ 1000mL 
from women without postpartum haemorrhage was poor, area under Receiver Operating 
Curve 0.53 (95% CI 0.49 to 0.58). For postpartum haemorrhage exceeding 2000mL of blood 
loss the area under Receiver Operating Curve was 0.60 (95% CI 0.52 to 0.68), showing an 
increase but still a rather poor discriminative power. Among 147 women with an abnormal 
bleeding score (≥4) the incidence of  postpartum haemorrhage of ≥ 1000mL was 18.4% 
(n=27), and the incidence of postpartum haemorrhage exceeding 2000mL was 8.8% 
(n= 13). Of the 1000 women with a normal bleeding score, 170 (17%) developed 
postpartum haemorrhage ≥1000mL and 42 (4.2%) developed  blood losses exceeding 
2000mL (Table 2). Results of the sensitivity analyses excluding women with an elective 
caesarean section were similar to those of the main analyses (S2). 
Bleeding symptoms
A history of postpartum haemorrhage was associated with  postpartum haemorrhages of 
≥ 1000mL and ≥2000mL. Epistaxis, post-surgery blood loss and a history of postpartum 
haemorrhage were associated with the development of blood loss exceeding 2000mL 
(Table 3). A total of 122 women had positive score on epistaxis or post-surgery blood loss, 
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Table 1.  Characteristics of participants
Postpartum 
haemorrhage ≥ 1000mL
Total LUMC Isala No Yes
Patients 1147 818 329 950 197









      Nulliparity 39% 41% 33% 38% 43%
      Gestational age 





















      Caesarean section 30% 33% 23% 30% 27%
      Vaginal 70% 67% 77% 70% 73%
Comorbidity
      Pre-eclampsia/HELLP 5% 5% 4% 4% 9%
      Anti-coagulant use 8% 10% 3% 8% 7%
      Known coagulation  
      disorder (VWD) 1% 5% 2% 1% 0%












    PPH ≥ 1000mL 17% 17% 16% NA NA
    PPH ≥ 2000mL 5% 4% 4% NA NA
*values are median (25-75 IQR), † primary cause of bleeding only reported in case of postpartum hemorrhage
Table 2.  Sensitivity and specificity, positive and negativ predictive 
  value of an abnormal bleeding score for the occurrence of   





































AUC, area under the curve; CI, confidence interval; PPH, postpartum hemorrhage. 
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Table 3.  Sensitivity and specificity, positive and negative predictive value of 
  bleeding symptoms for the occurrence of postpartum haemorrhage 
  ≥ 1000mL and ≥ 2000mL.
Sensitivity Specificity NPV PPV
Epistaxis
PPH 1000 4.6 95.5 82.8 17.3
PPH 2000 10.9 95.8 95.5 11.5
Cutaneous
PPH 1000 15.2 87.5 83.3 20.1
PPH 2000 18.2 87.3 95.5 6.7
Minor wounds
PPH 1000 3.6 95.8 82.7 14.9
PPH 2000 3.6 95.9 95.2 4.3
Oral Cavity
PPH 1000 66.0 31.2 81.5 16.6
PPH 2000 63.6 31.4 95.5 4.5
Gastrointestinal
PPH 1000 2.5 97.4 82.8 16.7
PPH 2000 1.8 97.3 95.2 3.3
Tooth extraction
PPH 1000 2.5 95.7 82.6 10.9
PPH 2000 3.6 96.0 95.2 4.3
Surgery
PPH 1000 8.1 93.5 83.1 20.5
PPH 2000 12.7 93.5 95.5 9.0
Menorrhagia
PPH 1000 16.2 82.8 82.7 16.4
PPH 2000 14.5 82.9 95.1 4.1
PPH
PPH 1000 30.5 84.2 85.4 28.6
PPH 2000 40.0 82.8 96.5 10.5
Muscle haematoma
PPH 1000 4.1 96.4 82.9 19.0
PPH 2000 1.8 96.2 95.1 2.4
Haemarthrosis
PPH 1000 1.5 99.3 82.9 30.0
PPH 2000 0.0 99.1 NA† NA
CNS 
PPH 1000 0.0 99.8 NA NA
PPH 2000 0.0 99.8 NA NA
Epistaxis & surgery
PPH 1000 12.2 89.7 83.1 19.7
PPH 2000 10.7 90.0 95.9 10.7
Incidence PPH 1000 mL in cohort 17.2%. Incidence PPH 2000 in cohort 4.2%. *Numbers are percentages.  
†Not calculated because of small numbers 
AUC, area under the curve; CI, confidence interval; PPH, postpartum haemorrhage. *abnormal bleeding score is 
defined as score >=4 
Discussion
This prospective two-centre cohort study describes the usefulness of a bleeding 
assessment tool to predict postpartum haemorrhage. In our cohort of 1147 women, the 
ability of the bleeding score to contribute to the discrimination between women with and 
without postpartum haemorrhage was poor.  
Our results suggest that a questionnaire does not contribute to the identification of 
women who will develop postpartum haemorrhage. Since the main causes for postpartum 
haemorrhage are obstetrical it might be not surprising that a tool initially developed for 
the diagnosis of bleeding disorders does not associate with postpartum haemorrhage. 
However, adding two questions on history of nosebleeds and post-surgery blood loss 
to a standard anamnesis does contribute to the identification of women with a higher 
risk of larger bleeds.  Especially in women with already known risk factors for postpartum 
haemorrhage, knowledge of an abnormal bleeding score could be of added value while 
composing a personalized birth plan.  
Strength and limitations of this study
A strength of our study is that we included a large cohort of 1147 pregnant women who 
had completed a bleeding assessment tool prior to childbirth with complete follow-up 
until childbirth.  To rule out the possibility of recall bias, the questionnaires were only 
completed by women before giving birth . Moreover, we used a self- BAT derived from the 
validated condensed MCMDM-1VWD-BAT which was proven to be a reliable tool. 
We can’t rule out the presence of bias in our study. A first possible source of bias is 
selection bias. In our cohort, the incidence of postpartum haemorrhage was higher 
than expected (17.2% versus expected 6-8%.).  This could be a result of the fact that the 
TeMpOH-2 study included women in a university hospital (LUMC) and a non-university 
hospital  with a NICU department on site, resulting in a population with a higher a priori 
risk of postpartum haemorrhage. Another possible explanation for the higher incidence 
of postpartum haemorrhage is the known underestimation of volume of blood loss in 
case of visual estimation. Volume of blood loss in theTeMpOH-2 study was objectively 
measured, which could have led to a more realistic, yet higher, incidence of postpartum 
haemorrhage. Yet, if anything, a higher incidence might have influenced the predictive 
value of the questionnaire in a positive way20,21. We therefore infer that the poor predictive 
value of our questionnaire is not the result of selection bias.
A second possible source of bias is misclassification of the endpoint postpartum 
haemorrhage. Volume of blood loss was supposed to be weighed in accordance  with the 
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visual estimation. When visual estimation is used, it is well-known that volume of blood 
loss is in most cases underestimated22. This may have led to potential misclassification of 
women in our cohort, which in this case may have caused an underestimation of incidence 
of post-partum haemorrhage. 
Notwithstanding the high incidence of postpartum haemorrhage, the discriminative 
power of our bleeding score to detect women with increased risk of postpartum 
haemorrhage was poor. This could mean, that the predictive ability of the bleeding score 
in a more general population of pregnant women is even worse. Although a less biased 
population would have made our results more generalizable, the results of our study into 
the predictive value of a bleeding score for prediction of postpartum haemorrhage are 
solid. 
Comparison with other studies
To the best of our knowledge, this study is the first to examine the value of bleeding scores 
acquired during pregnancy as a screening tool for the identification of women with an 
increased risk of excessive blood loss postpartum. Yet, our findings corroborate results of 
a previous studies in different patient populations. In a cohort of 7730 paediatric patients 
undergoing adenotonsillectomy, the efficacy of a preoperative bleeding questionnaire 
and coagulation screening in predicting haemorrhage associated with the procedure was 
studied18. When both an abnormal bleeding score and positive coagulation screening 
were combined, a statistically slightly higher likelihood of postoperative bleeding was 
found. However, an abnormal bleeding score without the additional coagulation screen 
did not have any predictive value for the occurrence of post-surgery haemorrhage. In a 
study in von Willebrand disease families (affected and unaffected family members), the 
association between spontaneous mucocutaneous bleeding symptoms and bleeding 
after tooth extraction or surgery was evaluated23. The mucocutaneous bleeding score 
showed a predictive value similar to VWF level for bleeding after tooth extraction (AUC 
0.71) and an even better value for prediction of bleeding after surgery (AUC 0.78). In the 
area of von Willebrand disease, bleeding scores are used for their high negative predictive 
value, indicating that a normal bleeding score can help exclude a clinically significant 
bleeding disorder24. In line with this, in a study of 217 individuals being prospectively 
investigated for von Willebrand disease, seventeen individuals with negative bleeding 
scores underwent major surgery, and none experienced significant bleeding. No previous 
studies were found that examined the predictive value of the use of bleeding scores in the 
field of childbirth. In contrast with von Willebrand disease, postpartum haemorrhage is a 
condition that is known for its multi-factorial origin. We have assessed that a high bleeding 
score can to a certain extent contribute to an individual patients risk assessment prior 
to birth. However, the question whether postpartum haemorrhage will actually occur, 
can only be answered during the course of active bleeding, depending on the obstetric 
challenges in tone, tissue, trauma and thrombin that will develop along the way 19. 
Clinical implications
No evidence was found to support adding a bleeding assessment tool to the review of a 
pregnant woman’s medical history for the prediction of postpartum haemorrhages of ≥ 
1000mL. However, adding two questions on history of nosebleeds and post-surgery blood 
loss to a standard anamnesis could enable a clinician to identify women with a higher risk 
of postpartum haemorrhage exceeding 2000mL. Clinicians should contemplate whether 
they find this of clinical significance for individual patients.  Especially in women with 
already known risk factors for postpartum haemorrhage, knowledge of an abnormal 
bleeding score could be of added value while composing a personalized birth plan.  
 
Conclusion
When used as a screening tool contributing to  the identification of pregnant women 
with an increased risk of postpartum haemorrhage prior to childbirth, a bleeding 
questionnaire lacks discriminative power. We found no evidence to support the added 
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Supplemental material
S1  TeMpOH-2 Self-BAT
S2  Table: Sensitivity analyses: cohort after exclusion of women with elective cesarean 
section. Sensitivity and specificity, positive and negative predictive value of 
an abnormal bleeding score for the occurrence of postpartum haemorrhage 
≥ 1000mL and ≥ 2000mL.
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S2  Sensitivity analyses: cohort after exclusion of women with elective caesarean 
section. Sensitivity and specificity, positive and negative predictive value of 
an abnormal bleeding score for the occurrence of postpartum haemorrhage 




PPH≥2000 Sensitivity Specificity NPV PPV
(n=945) 0.52 (0.47 – 0.57) 0.58 (0.50 - 0.66) NA NA NA NA
PPH ≥ 1000 NA NA 12.4 87.1 82.0 17.4
PPH ≥ 2000 NA NA 19.6 95.0 95.0 8.3
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Abstract
Background: We describe the pattern of change in coagulation parameters during the 
course of severe postpartum haemorrhage.
Methods: Retrospective cohort study among 1312 women experiencing severe 
postpartum haemorrhage necessitating blood transfusion. Levels of haemoglobin, 
haematocrit, platelet count, fibrinogen, aPTT and PT per categorized volume of blood loss 
during severe postpartum haemorrhage were described and compared between women 
with and without the composite adverse outcome. Need for surgical intervention, severe 
acute maternal morbidity and maternal mortality were jointly considered the composite 
adverse outcome.
Findings:  Of the 1312 women, 463 (35%) developed the composite adverse outcome. 
The incidence of a fibrinogen level <2 g/L was 26% (342 per 1312). Low fibrinogen 
and prolonged aPTT during the first two litres of haemorrhage were associated with a 
subsequent composite adverse outcome; median fibrinogen and aPTT among women 
with and without the composite endpoint after 1.5-2 L of haemorrhage were 1.5 g/L (IQR 
1.0 to 1.9) vs 2.7 g/L (IQR 1.9 to 3.4) and 39s (IQR 30 to 47) vs 32 s (IQR 28 to 36) respectively. 
PT and platelet count as assessed during the first two litres of haemorrhage were not 
associated with morbidity or mortality. 
Interpretation: Our results suggest that detection of low levels of fibrinogen and elevated 
aPTT levels during early postpartum haemorrhage can contribute to the identification 
of women that may benefit from targeted haemostatic treatment. Essential in this 
identification process is the moment of reaching a level of fibrinogen of <2 g/L during the 
course of postpartum haemorrhage.
Introduction
Postpartum haemorrhage is a major cause of maternal morbidity and mortality with an 
incidence that seems to be increasing over the last decade1-8 . 
Efforts to prevent morbidity and mortality due to postpartum haemorrhage focus among 
other things on laboratory monitoring of haemostasis in order to enable timely treatment 
of possible coagulopathy. Haemostasis may be monitored by laboratory-based PT/aPTT, 
Clauss fibrinogen, platelet count, and point of care testing9. Experts recommend that all 
these may be used simultaneously because there is currently no high level evidence on 
the best strategy9. This advice leads to inefficiency, waste and considerable variation in 
the care for patients with postpartum haemorrhage. 
In order to determine the optimal strategy to monitor coagulopathy, it is crucial to 
know the patterns of changes in coagulation parameters in relation to the phases of 
postpartum haemorrhage and to identify which parameters show the fastest changes 
associated with the risk of severe maternal outcomes. Data on the change in coagulation 
parameters during the course of postpartum haemorrhage, thus per litre of ongoing 
haemorrhage, are limited. Earlier studies used repeated measurements at set time points 
or reported worst values in the course of bleeding10-12. Some have suggested that low 
fibrinogen concentration might be the earliest predictor of progression towards severe 
postpartum haemorrhage11,13,14. Investigators studying women with severe postpartum 
haemorrhage face the enormous challenge of including women in a life-threatening 
condition, frequently leading to failure to include the most severe cases. 
Diligent observation of present-day monitoring of haemostasis and outcomes among 
an unselected cohort of women with ongoing postpartum haemorrhage may help to 
identify the haemostasis parameters that are able to recognize women with a high risk for 
morbidity and mortality as early as possible during postpartum haemorrhage.
The aim of this study was to describe coagulation parameters including fibrinogen during 
the course of severe postpartum haemorrhage -per categorized volume of blood loss. 
Also, coagulation parameters during early postpartum haemorrhage  were compared 
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Methods
Design and study population
The Transfusion strategies in women during Major Obstetric Haemorrhage-1 (TeMpoH-1) 
study is a nationwide retrospective cohort study in 61 hospitals in the Netherlands. 
TeMpOH-1 included  women who received at least four units of red cells or any transfusion 
of fresh frozen plasma (FFP) and/or platelets in addition to red cells because of severe 
obstetric haemorrhage (≥1000 mL blood loss during pregnancy, birth or puerperium). For 
the present analysis we selected women from the TeMpOH-1 cohort who met criteria 
for primary postpartum haemorrhage (blood loss (≥1000 mL occurring within the first 24 
hours after childbirth). We excluded women for whom we did not have any coagulation 
parameter measured between childbirth and end of active postpartum haemorrhage. 
Women 18 years of age and older who met the inclusion criteria were selected. Women 
with a known coagulation disorder or anticoagulant were included in the study. Approval 
for the TeMpOH-1 study was obtained from the Medical Ethical Research Committee 
of the Leiden University Medical Centre (P12.273) and from the institutional review 
board of each participating hospital. The study was registered in the Netherlands 
Trial Register (NTR4079). Detailed design of the study has been reported elsewhere 15. 
Because of the retrospective design of the study, the need to obtain informed consent 
from eligible women was waived by the ethics committee. Eligible women were selected 
from transfusion databases and birth registries of participating hospitals with 191.772 
births between 2011 and 2013. By cross-referencing electronic data from the hospitals’ 
blood transfusion services with local birth registers in participating hospitals, all women 
experiencing severe postpartum haemorrhage necessitating blood transfusion during the 
inclusion period of the study could be included.  In most hospitals no pregnancy specific 
massive transfusion protocol is available and in most cases the normal (non-pregnancy) 
target values for haemostatic therapy are used: haemoglobin 8 g/dL, PT and aPTT < 1.5x 
prolonged, platelet count > 50-100 x 109/L and fibrinogen > 1.5 g/l.
Data collection
Detailed information on maternal, pregnancy and birth characteristics was collected from 
medical files. Chart reviews were conducted by trained medical students and research 
nurses. Data were recorded from files available at the maternity ward, operating theatre and 
intensive care unit for the following parameters: maternal age at the time of birth, parity, 
maternal body weight during early pregnancy, maternal height, ethnicity, gestational 
age, obstetric history, mode of birth, cause of major obstetric haemorrhage, abnormal 
placentation, shock, timing and volume of fluids and blood products administered, timing 
of surgical and haemostatic interventions and consecutive measurements of blood loss 
until cessation of bleeding. Blood loss was measured by weighing gauzes and other 
soaked materials and by use of a collector bag and suction system in the operating theatre. 
Laboratory parameters
Of the included women, we documented available laboratory parameters and data on 
type and volume as well as timing of clear fluids and blood products administered during 
the course of postpartum haemorrhage, haemoglobin level (Hb g/dl), haematocrit (Ht, 
fraction), platelet count (x109/litre), activated partial thromboplastin time (aPTT, seconds), 
prothrombin time (PT, seconds) and fibrinogen (g/l). Laboratory parameters from the first 
measurement of blood loss onwards were considered, including parameters drawn from 
women before they had reached 1000mL of blood loss. Unlikely values were verified in the 
medical records.  There was no pre-set protocol for obtaining specimens: blood samples 
during postpartum haemorrhage had been obtained on request of the care giver leading 
to different numbers and panels of results of laboratory parameters.
Composite adverse maternal outcome
Emergency peripartum hysterectomy, ligation of the uterine arteries, B-Lynch suture (in 
the Netherlands only used as emergency procedure), arterial embolization or admission 
into an intensive care unit were jointly considered the combined endpoint of severe acute 
maternal morbidity. Women were compared with regard to whether they had developed 
a composite adverse maternal outcome consisting of severe acute maternal morbidity, 
maternal mortality or need for surgical intervention.  
Statistical analyses
Coagulation parameters are presented as median and interquartile ranges because of non-
Gaussian distribution. The phases of ongoing postpartum haemorrhage were categorized 
according to increasing volumes of blood loss: 0-1L, 1-1.5L, 1.5-2L, 2-2.5L, 2.5-3L, 3-3.5L, 
3.5 and >4L. Each laboratory parameter result was assigned to the category of blood loss 
at which the respective blood sample had been taken. In case of multiple measurements 
per woman within one category of volume of blood loss, the mean of those values was 
used. In order to assign a volume of blood loss for each of the laboratory parameters 
we imputed volumes of blood loss using linear interpolation of  two consecutive blood 
volume measurements. In case total blood loss was the only available data point, or the 
blood sample was drawn before the first measurement of blood loss volume, the birth 
time of the baby was used as the starting point for the interpolation. Levels of coagulation 
parameters between groups were compared with Mann-Whitney U tests. Reference 
ranges of aPTT varied somewhat for the 61 participating hospitals as a result of use of 
different types of reagents. To examine the robustness of aPTT results we repeated the 
analyses using aPTT ratios, which were calculated by dividing the observed aPTT levels by 
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Results
Patient characteristics
Over the two-year inclusion period of the TeMpOH-1 study, 1391 women had received at 
least four units of red cells, or fresh frozen plasma or platelets in addition to red cells for 
postpartum haemorrhage. A total of 1312 women with primary postpartum haemorrhage 
had at least one valid measurement of coagulation parameters sampled during active 
bleeding (Figure 1). The median volume of blood loss among these 1312 women was 3 L 
(interquartile range (IQR) 2.5 to 4.0). Characteristics of the study population and of women 
with and without the composite adverse outcome are reported in Table 1. 
Figure 1.  Inclusion flowchart  for ‘coagulation parameters during the course  
  of severe postpartum haemorrhage: a nationwide retrospective   
  cohort study’
Table 1.  Patient and treatment characteristics of the total study population  
  and according to the development of the composite adverse   
  outcome
Severe acute maternal morbidity, 
mortality, and need for surgical 
intervention
Patient and treatment characteristics Total No Yes
Patients, n (%) 1312 849 (65) 463 (35)
Maternal characteristics
Age, y 31.3 (28-35) 31.0 (28-35) 32.0 (29-35)
Body mass index, kg/m2 23.3 (21-26.4) 23.1 (20.9-26.3) 23.5 (21-27)
Ethnicity, white, % 71 75 65
Nulliparity, % 52 54 47
Gestational age, wk 39.6 (38-40.7) 39.7 (38.3-40.9) 39.4 (37.4-40.6)
Mode of birth, %
Caesarean section 25 19 36
Vaginal 75 81 63
Comorbidity, %
Preeclampsia/HELLP 11 9 14
Anticoagulant use 0.5 0.5 0.7
Transfer to hospital, %
Transfer to hospital during labor 14 15 12
Postpartum transfer (birth at home) 12 15 8
Primary cause of bleeding, %
Uterine atony 65 66 63
Retained placenta 17 21 10
Pathological ingrowth of placenta 8 6 12
Placenta previa 1 1 2
Surgical bleeding 7 5 10
Placental abruption 2 2 2
Coagulopathy 1 0 1
Fibrinogen administered, % 10 4 21
Tranexamic acid administered, % 44 36 59
Recombinant FVIIa-administered, % 3 0.1 8
Bleeding rate, mL/min* 2.4 (1.2-4.6) 2.3 (1.2-4.2) 2.4 (1.3-5.3)
Shock (systolic blood pressure ,90 or 
heart rate .120), %
85 84 86
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Severe acute maternal morbidity, 
mortality, and need for surgical 
intervention
Patient and treatment characteristics Total No Yes
Total units of blood products 6.0 (4.0-8.0) 5.0 (4.0-6.0) 10.0 (6.0-16.0)
Four or more red cells units, n (%) 875 (67) 481 (57) 394 (85)
One to 3 red cells and 1 or more plasma 
units, n (%)
427 (33) 360 (42) 67 (14)
One to 3 red cells and 1 or more 
platelets units, n (%)
10 (1) 8 (1) 2 (0.4)
Total volume of blood loss, L 3.0 (2.5-4.0) 2.8 (2.2-3.3) 4.0 (3.0-5.5)
Values are median (IQR), except as noted.
*Maximum.
Laboratory parameters during postpartum haemorrhage 
Haemoglobin concentration was measured on 2605 occasions, haematocrit on 2245 
occasions, platelet count on 1581 occasions, fibrinogen concentration on 775 occasions, 
PT on 876 occasions, and aPTT on 1075 occasions. Women had a median amount of 3 (IQR 
2 to 5) blood loss measurements during active postpartum haemorrhage.  Figure 2 shows 
results of the laboratory test results according to increasing volumes of haemorrhage. 
The accompanying patient count, mean, standard deviation, median, interquartile range, 
lowest and highest values of laboratory parameters according to increasing volumes of 
blood loss are presented in supplemental table S1. Levels of haemoglobin tended to 
decrease up to 2.0-2.5L of blood loss to a haemoglobin level of 7.7 g/dL (IQR 6.4-9.0) and 
a haematocrit of 0.24 (IQR 0.20-0.28), after which stabilization occurred.  At 2.5L of blood 
loss 203 out of 443 (46%) women had been transfused with blood products. 
Platelet counts also decreased with increasing volume of blood loss. Women with 2.0-2.5L 
of blood loss, had a median platelet count of 146 X109/litre (IQR 108-186). Four percent 
(10/253) of these women had received a platelet transfusion at that time. For 128 women 
with blood loss of 3.5-4.0L the median platelet count was 115X109/litre (IQR 89-143); 21 
of these 128 (16%) women had received platelet transfusions and 113/128 (88%) had 
received a blood product. 
Figure 2.  Coagulation parameters of women during the course of severe   
  postpartum haemorrhage per categorized amount of blood loss. 
Coagulation parameters of women during the course of severe postpartum haemorrhage per categorized amount 
of blood loss. Laboratory parameters are presented in box plots.  Circles are outliers. The box represents the 25th 
and 75th percentiles and the whiskers are the upper and lower adjacent values.
Continuing Table 1. Patient and treatment characteristics of the total study   
  population and according to the development of the composite   
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Figure 3.  Coagulation parameters  of women with and without combined   
  endpoint of severe acute maternal morbidity, mortality or need for  
  surgical intervention per categorized volume of blood loss
Coagulation parameters  of women with and without combined endpoint of severe acute maternal morbidity or 
mortality  per categorized amount of blood loss. Box plots of coagulation parameters per categorized amount of 
blood loss comparing women experiencing postpartum haemorrhage with and without the composite adverse 
outcome. Morbi-mortality comprises the composite adverse outcome of  severe acute maternal morbidity and 
mortality.  Circles are outliers. The box represents the 25th and 75th percentiles and the whiskers are the upper 
and lower adjacent values.
There were 342 (0.18% of all births in the 61 hospitals and 26% of the women in our study 
cohort) women who developed a fibrinogen level below 2 g/L. A fibrinogen level below 
1 g/L was reached by  78 women. Five percent (70/1312) of the women in our cohort 
reached a fibrinogen level below 2 g/L after losing less than 2L of blood. Four women 
reached this level because of postpartum haemorrhage due to placental abruption. 
Median baseline fibrinogen level during early postpartum haemorrhage was 2.8 g/L (IQR 
1.6-4.3). Fibrinogen levels tended to decrease up to 2-2.5L of blood loss at 2.1 g/L (IQR 1.6-
2.7). Among 152 women who had lost more than 4L, median level of fibrinogen was 1.8 
g/L (IQR 1.4-2.2); 41% of these women had been treated with fibrinogen concentrates. In 
the subgroup of  patients with postpartum haemorrhage due to uterine atony or retained 
placenta we observed a similar trend (Figure S4). 
Median PT values showed a slight increase with increasing volumes of blood loss. During 
the earliest phase of postpartum haemorrhage median PT was 12.7 seconds (IQR 10.7-
15.9); among women who lost more than 4 L the median PT was 14.9 (IQR 12.0-17.5). 
Median aPTT increased with increasing volumes of blood loss from 30.0 seconds (IQR, 
27.0-35.0) during early bleeding to 37.5 seconds (IQR 32.0-43.6) in the maximum blood 
loss category. Sensitivity analyses on the aPTT ratio showed similar results (S5). 
Laboratory parameters and adverse maternal outcome 
Of the 1312 women 463 (35%) developed a combined endpoint of severe acute maternal 
morbidity mortality or the need for surgical intervention; 37% (172/463 women) of 
these women developed more than one of the items composing the combined adverse 
endpoint.  To arrest bleeding, hysterectomy was necessary in 72 (5%) women, 164 (13 
%) were treated with arterial embolisation, in 46 (4%) women an emergency B-lynch 
procedure or ligation of arteries was performed. Of the women in our study cohort, 386 
(29%) were admitted to the ICU and 7 (0.5%) died as a result of severe haemorrhage. 
Figure 3 shows laboratory results during postpartum haemorrhage of women with and 
women without the composite adverse outcome. Women who developed the composite 
adverse outcome had lower fibrinogen concentrations and longer aPTTs than women 
who did not develop the endpoint, which was already apparent and most pronounced 
during the earliest phases of postpartum haemorrhage. There were no noteworthy 
differences in haemoglobin, haematocrit, PT and platelet levels during the early phases 
of postpartum haemorrhage (blood loss below 2L, Table 2). Women who developed the 
composite adverse outcome had a median fibrinogen level of <2g/L at 1.5-2L of blood 
loss, whereas women without the composite adverse outcome had a median fibrinogen 
of <2 g/L after a volume of more than 3.5L of blood loss. Additional results based on first 
sample during postpartum haemorrhage, irrespective of blood loss volume and ROC 
analyses of progression to the severe morbidity endpoint based on the first blood test are 
provided in the Supplemental Data (Table S2 & S3). Sensitivity analyses with the aPTT-ratio 
showed similar results (Table S6). Patient characteristics of the women with fibrinogen 






















































































































































































































































































































































































































































































































































Among women with severe postpartum haemorrhage requiring blood transfusion, the 
occurrence of low levels of fibrinogen and prolonged aPTTs in the earliest phases of 
haemorrhage was associated with progression toward severe acute maternal morbidity, 
mortality or need for surgical intervention. 
Strength and limitations of this study
Our study describes coagulation parameters and morbidity of women with severe 
postpartum haemorrhage. The results are therefore only generalizable to women 
suffering severe postpartum haemorrhage. The unique strength of this retrospective 
study is that we were able to include all women with severe postpartum haemorrhage 
necessitating blood transfusion that had occurred in the 61 participating hospitals during 
the study period, including the most severe cases, enabling reliable and generalizable 
estimation of percentages of women with coagulopathy during the course of postpartum 
haemorrhage. In addition, the large sample size allowed us to examine patterns of 
laboratory parameters throughout the course of on-going postpartum haemorrhage. The 
retrospective study design also has limitations. We did not have control over the number 
and specific panels of coagulation samples. Therefore, our results are based on different 
selections of women in the categories of blood loss. Obviously more blood samples were 
drawn from women with more severe bleeding. It is therefore possible that women with 
low fibrinogen or prolonged aPTT were missed in women with lower blood loss as these 
parameters were not measured, because there were no measurements. This may have led 
to an underestimation of the occurrence of abnormal laboratory parameters. Moreover, 
laboratory measurements were performed in local laboratories of the 61 hospitals, 
leading to significant variation in measurements and possible misclassification. Such 
variation will also influence the results towards underestimation of the strength of the 
association of coagulation parameter abnormalities with morbidity and mortality. To be 
certain of the accuracy of all low fibrinogen values in our study cohort, we returned to the 
61 participating hospitals and verified all values of fibrinogen with a level < 2g/L (and all 
other outliers of laboratory parameters) in the medical files. During the inclusion period 
of our study none of the participating hospitals used thromboelastometry in women 
experiencing postpartum haemorrhage.
Comparison with other studies
The occurrence of coagulopathy in postpartum haemorrhage and its association with 
maternal morbidity and mortality has been studied previously. For a correct interpretation 
of the results of this study in the context of previous studies, it should be taken into account 
that our study differs from previous studies as regards to its source population: as opposed 
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administration of blood products were included. Fibrinogen levels of lower than 2 g/L 
were strongly associated with progression towards severe postpartum haemorrhage 
in a study among 128 women with postpartum haemorrhage11. However, in this study 
measurements were done at predefined hours after enrolment and information on the 
corresponding amount of blood loss at the time of the measurements was lacking. It 
therefore remained unclear whether the level of fibrinogen was a predictor of progression 
towards more severe bleeding or a result of blood loss at time of blood sampling. Another 
study among 456 women with postpartum haemorrhage from a large UK unit reported 
results of haemoglobin, platelet count, PT and aPTT tests that were categorized based on 
the worst value of the total amount of blood loss at the end of bleeding10. Fibrinogen was 
found to be the parameter that best correlated with increasing volume of haemorrhage. 
PT and aPTT remained within the normal range in most women despite large bleeds. 
In a review article Collis et al summarized results of five studies that tried to determine 
a value of fibrinogen that could serve as a biomarker for progression of postpartum 
haemorrhage14. These values varied between studies: fibrinogen level 3.3/3.4/1.8/3.1/2.8 
g/L10,11,13,16,17. Their overall conclusion was that a fibrinogen level of < 3 g/L and, in particular 
< 2 g/L was associated with progression towards more severe postpartum haemorrhage.
 
Another study on women in need of massive transfusion because of postpartum 
haemorrhage (≥8 units of red cells within 24 hours of delivery ) was also based on the 
first and worst values measured, regardless of volume of blood loss at sampling12. Also, in 
this study a difference was made between levels of coagulation parameters for different 
primary causes of bleeding. Since the primary cause of bleeding often remains unclear 
during active postpartum haemorrhage, and in some cases is only clarified when additional 
tests have been performed after the event, we find it of great clinical importance to study 
the pattern of change of coagulation parameters over time in relation to volume of blood 
loss, regardless of primary cause of bleeding.
In our cohort we observe a higher occurrence of a fibrinogen concentration below 
2 g/L compared to results suggested in randomized trials. This can be explained by 
differences in patient selection. In a Danish multicentre double-blind randomized trial, 
women experiencing severe postpartum haemorrhage were treated with a dose of 2 
gram of fibrinogen concentrate or placebo18. Of the 244 randomized women, only five 
had a fibrinogen value less than 2 (mean value in both groups 4.5). A more recent trial 
randomized 55 women at a FIBTEM® value of 15 mm (considered to be the equivalent to 
Clauss fibrinogen value of 3 g/L) to fibrinogen concentrate or placebo19. No improvement 
in outcome was observed in women who were administered fibrinogen; only 7 women 
(out of a cohort of 663 women with postpartum haemorrhage) developed a fibrinogen 
level below 2 g/L confirming, as discussed by the authors, the challenges related to 
consenting women with severe bleeding and undertaking trial procedures whilst treating 
acutely ill women. This challenge was also experienced by a Finnish research group 
who aimed to perform a randomized controlled trial comparing  prothrombin complex 
concentrate and  fibrinogen concentrate to fresh frozen plasma as a treatment for women 
experiencing postpartum haemorrhage exceeding 2 litres (NCT01910675). Obtaining 
informed consent in an acute situation with severe bleeding turned out to be impossible 
(personal communication). 
The results of the TeMpOH-1 study confirm the results of previous studies into this subject, 
however with one very important addendum for acute clinical decision-making: the 
dimension of time. We found 342 women with a fibrinogen level ≤ 2 g/L and a further 78 
women with a fibrinogen level ≤1 g/L. We have elucidated that women who experienced 
postpartum haemorrhage without developing a composite outcome of maternal 
morbidity and mortality only sporadically reached a fibrinogen value of <2 g/L (blood loss 
above 3.5 litres). Women who did develop the composite adverse outcome reached this 
low fibrinogen level much earlier (1.5-2L of blood loss) during postpartum haemorrhage. 
This difference in the moment of reaching a level of fibrinogen of <2 g/L during the course 
of postpartum haemorrhage is essential for the selection of the right target population for 
future studies into the potential benefit of administering fibrinogen concentrate. 
Clinical implications
By the timely detection of changes in levels of relevant coagulation parameters, targeted 
haemostatic therapy to restore deficiencies could be administered. However, assessment 
of fibrinogen levels by a standard coagulation test like the Clauss fibrinogen assay has 
a turn-around time of up to 60 minutes making it unsuitable for acute clinical decision 
making20. Point-of-care devices like ROTEM® thromboelastometry are able to detect 
essential changes in the coagulation system within 10 minutes after blood sampling21. 
ROTEM FIBTEM could potentially be a worthwhile addition to postpartum haemorrhage 
management.  To make progress in this field we need to monitor women experiencing 
postpartum haemorrhage closely during the process of active blood loss. In our next 
currently ongoing study (NCT02149472) we will further elucidate the predictive value 
of early changes in coagulation parameters (including thromboelastometry) for the 
development of severe acute maternal morbidity and mortality in women experiencing 
postpartum haemorrhage. The results provided by this study provide a solid knowledge 
base to be used when making the transition towards the evidence based use of rapid 
point of care testing.   
Conclusion
In this nationwide retrospective cohort study on the change of coagulation parameters in 
1312 women experiencing severe postpartum haemorrhage requiring blood transfusion, 
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parameters during postpartum haemorrhage. Our results suggest that detection of low 
levels of fibrinogen and elevated aPTT levels during early postpartum haemorrhage can 
contribute to the identification of women that may benefit from targeted haemostatic 
treatment. Based on these results we advise to assess levels of fibrinogen and aPTT in all 
women who experience postpartum haemorrhage with blood loss exceeding 1L. 
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S4  Fibrinogen value for postpartum haemorrhage cases due to retained placenta and 
atony
S5  Sensitivity analyses: patient count, median, IQR  and figure for aPTT- ratio
S6  Sensitivity analyses: Adverse maternal outcome & coagulation parameters 
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S1  Patient counts, mean, median, IQR per coagulation parameter 
Haemoglobin
Blood loss n mean sd p50 p25 p75 min max
0.00 to 1.0 (L) 301 9.8 2.20 10.0 8.3 11.6 4.0 15.0
1.01 to 1.5 (L) 395 9.1 2.18 9.3 7.6 11.0 3.2 14.0
1.51 to 2.0 (L) 430 8.3 2.09 8.2 6.9 9.7 1.9 14.7
2.01 to 2.5 (L) 443 7.8 1.87 7.7 6.4 9.0 3.2 13.4
2.51 to 3.0 (L) 369 7.7 1.68 7.7 6.6 8.9 3.5 13.2
3.01 to 3.5 (L) 256 8.1 1.78 8.1 6.8 9.3 4.0 13.2
3.51 to 4.0 (L) 171 8.1 1.74 8.2 7.1 9.3 2.7 12.7
4.01 or more (L) 240 8.5 1.72 8.4 7.4 9.5 3.9 15.1
Total 2605 8.4 2.06 8.3 7.0 9.7 1.9 15.1
Haematocrit
Blood loss n mean sd p50 p25 p75 min max
0.00 to 1.0 (L) 265 0.30 0.06 0.30 0.25 0.35 0.13 0.45
1.01 to 1.5 (L) 357 0.28 0.06 0.28 0.23 0.33 0.10 0.41
1.51 to 2.0 (L) 369 0.25 0.06 0.25 0.21 0.29 0.07 0.43
2.01 to 2.5 (L) 363 0.24 0.05 0.24 0.20 0.28 0.10 0.39
2.51 to 3.0 (L) 320 0.23 0.05 0.23 0.20 0.26 0.12 0.40
3.01 to 3.5 (L) 209 0.25 0.05 0.25 0.21 0.27 0.12 0.40
3.51 to 4.0 (L) 145 0.24 0.05 0.24 0.21 0.28 0.08 0.38
4.01 or more (L) 217 0.25 0.05 0.25 0.22 0.28 0.12 0.47
Total 2245 0.25 0.06 0.25 0.21 0.30 0.07 0.47
Platelet count
Blood loss n mean sd p50 p25 p75 min max
0.00 to 1.0 (L) 130 172 75.61 171 116 229 30 420
1.01 to 1.5 (L) 194 164 72.05 164 113 210 15 357
1.51 to 2.0 (L) 226 154 65.21 146 108 199 1 387
2.01 to 2.5 (L) 253 150 60.15 146 108 186 13 375
2.51 to 3.0 (L) 263 132 53.59 128 97 164 15 380
3.01 to 3.5 (L) 167 121 46.47 115 89 149 30 285
3.51 to 4.0 (L) 128 117 44.24 115 89 143 35 288
4.01 or more (L) 220 102 39.85 95 74 123 30 259
Total 1581 138 62.08 130 94 176 1 420
Fibrinogen
Blood loss n mean sd p50 p25 p75 min max n <=1 n <=2
0.00 to 1.0 (L) 52 3.0 1.70 2.8 1.6 4.3 0.2 6.2 8 17
1.01 to 1.5 (L) 75 2.9 1.37 2.7 1.8 3.6 0.2 6.5 6 22
1.51 to 2.0 (L) 79 2.3 1.25 2.1 1.4 3.1 0.2 5.6 13 39
2.01 to 2.5 (L) 115 2.1 0.84 2.1 1.6 2.7 0.2 5.3 10 54
2.51 to 3.0 (L) 133 2.1 0.80 1.9 1.6 2.6 0.2 4.3 11 75
3.01 to 3.5 (L) 94 2.1 0.79 2.0 1.6 2.6 0.6 4.9 7 48
3.51 to 4.0 (L) 75 1.9 0.86 1.8 1.5 2.3 0.1 5.9 7 53
4.01 or more (L) 152 1.8 0.63 1.8 1.4 2.2 0.2 4.0 13 102
Total 775 2.2 1.05 2.0 1.5 2.7 0.1 6.5 75 410
PT
Blood loss n mean sd p50 p25 p75 min max
0.00 to 1.0 (L) 49 13.5 3.86 12.7 10.7 15.9 9.2 25.0
1.01 to 1.5 (L) 79 13.6 2.64 13.5 11.2 15.4 9.7 20.6
1.51 to 2.0 (L) 94 14.7 7.02 13.6 11.9 15.3 9.6 74.3
2.01 to 2.5 (L) 130 16.1 9.11 14.7 11.9 17.0 9.3 90.0
2.51 to 3.0 (L) 163 14.5 3.31 14.1 11.9 16.0 8.5 31.0
3.01 to 3.5 (L) 107 14.3 2.58 14.2 12.2 16.3 10.1 22.5
3.51 to 4.0 (L) 87 17.1 15.42 14.3 12.3 16.2 10.9 120.0
4.01 or more (L) 167 16.5 9.00 14.9 12.0 17.5 6.9 79.6
Total 876 15.2 7.87 14.1 11.9 16.3 6.9 120.0
APTT
Blood loss n mean sd p50 p25 p75 min max
0.00 to 1.0 (L) 71 36.1 18.28 30.0 27.0 35.0 24.0 120.0
1.01 to 1.5 (L) 105 33.0 7.27 31.0 28.0 36.0 23.7 65.0
1.51 to 2.0 (L) 121 36.4 13.60 33.0 29.0 39.0 21.0 120.0
2.01 to 2.5 (L) 160 37.5 13.70 34.0 30.0 41.3 19.4 120.0
2.51 to 3.0 (L) 199 36.7 10.71 34.1 30.0 40.0 22.9 120.0
3.01 to 3.5 (L) 134 36.0 9.57 34.6 30.0 40.0 21.0 80.0
3.51 to 4.0 (L) 97 38.9 15.81 35.0 31.3 40.0 11.0 120.0
4.01 or more (L) 188 41.7 17.63 37.5 32.0 43.6 11.0 120.0
















































































































































































































































































































































































































































































































































































































































































































S3  ROC analyses of progression to the severe morbidity endpoint based on   
 the first blood test
AUC First sample Blood loss  1.0 to 1.5  (L)
Blood loss 
1.5 to 2.0  (L)
Fibrinogen 0.646 (0.603 to 0.689)* 0.661 (0.529 to 0.793) 0.720 (0.597 to 0.843)
aPTT 0.630 (0.590 to 0.670) 0.616 (0.503 to 0.729) 0.655 (0.549 to 0.761)
Haemoglobin 0.519 (0.487 to 0.551) 0.551 (0.489 to 0.612) 0.489 (0.426 to 0.551)
Haematocrit 0.517 (0.482 to 0.552) 0.546 (0.481 to 0.611) 0.487 (0.420 to 0.554)
Platelet count 0.581 (0.546 to 0.617) 0.539 (0.452 to 0.626) 0.522 (0.442 to 0.602)
PT 0.538 (0.493 to 0.584) 0.534 (0.394 to 0.673) 0.568 (0.431 to 0.706)
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S4 Fibrinogen value for postpartum haemorrhage cases due to retained   
 placenta and atony
Blood loss n p50 p25 p75
0.00 to 1.0 (L) 34 2.5 1.6 3.9
1.01 to 1.5 (L) 52 2.8 1.9 3.5
1.51 to 2.0 (L) 48 2.2 1.7 3.4
2.01 to 2.5 (L) 75 2.1 1.7 2.7
2.51 to 3.0 (L) 94 1.9 1.6 2.5
3.01 to 3.5 (L) 62 2.0 1.6 2.7
3.51 to 4.0 (L) 51 1.8 1.4 2.3
4.01 or more (L) 92 1.7 1.3 2.2
Blood loss n p50 p25 p75
0.00 to 1.0 (L) 8 4.1 3.5 4.8
1.01 to 1.5 (L) 5 4.4 2.3 4.6
1.51 to 2.0 (L) 14 2.8 1.4 3.1
2.01 to 2.5 (L) 18 2.0 1.3 2.5
2.51 to 3.0 (L) 13 1.6 1.3 2.0
3.01 to 3.5 (L) 16 2.0 1.6 2.5
3.51 to 4.0 (L) 11 1.7 1.5 1.9
4.01 or more (L) 12 1.8 1.3 2.0
Blood loss n p50 p25 p75
0.00 to 1.0 (L) 10 3.4 1.1 4.9
1.01 to 1.5 (L) 18 2.4 1.7 3.4
1.51 to 2.0 (L) 17 1.5 1.3 2.0
2.01 to 2.5 (L) 22 2.0 1.4 2.6
2.51 to 3.0 (L) 26 2.4 1.8 3.1
3.01 to 3.5 (L) 16 2.1 1.5 2.4
3.51 to 4.0 (L) 13 1.9 1.6 2.6
4.01 or more (L) 48 1.9 1.5 2.3
 
Fibrinogen value for postpartum haemorrhage cases due to atony, retained placenta and other causes. 
Laboratory parameters are presented in box plots.  Circles are outliers. The box represents the 25th and 75th 
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S5 Sensitivity analyses:  patient count, median, IQR  and figure for aPTT- ratio
Blood loss n mean sd p50 p25 p75 min max
0.00 to 1.0 (L) 68 1.27 0.66 1.08 0.93 1.25 0.80 4.36
1.01 to 1.5 (L) 94 1.14 0.27 1.11 0.95 1.27 0.76 2.17
1.51 to 2.0 (L) 105 1.27 0.49 1.16 0.98 1.32 0.72 3.89
2.01 to 2.5 (L) 135 1.31 0.47 1.18 1.04 1.46 0.74 3.64
2.51 to 3.0 (L) 179 1.27 0.39 1.18 1.04 1.36 0.80 4.00
3.01 to 3.5 (L) 121 1.23 0.33 1.16 1.01 1.39 0.73 2.79
3.51 to 4.0 (L) 83 1.29 0.41 1.21 1.04 1.40 0.39 3.46
4.01 or more (L) 171 1.43 0.61 1.30 1.13 1.49 0.39 4.62
Total 956 1.29 0.47 1.18 1.03 1.40 0.39 4.62
Sensitivity analyses: patient count, median, IQR and figure for aPTT-ratio. Laboratory parameters are presented 
in box plots.  Circles are outliers. The box represents the 25th and 75th percentiles and the whiskers are the 
upper and lower adjacent values.
S6  Sensitivity analyses: Adverse maternal outcome & coagulation parameters  
 aPTT- ratio 
Blood loss
Category





No Yes P* No Yes P*
0.00 to 1.0 (L) 29 31 0.11 1.01 1.12 0.04
1.01 to 1.5 (L) 30 32 0.03 1.02 1.14 <0.01
1.51 to 2.0 (L) 32 39 <0.01 1.13 1.31 <0.01
2.01 to 2.5 (L) 33 37 <0.01 1.14 1.34 <0.01
2.51 to 3.0 (L) 33 38 <0.01 1.14 1.30 <0.01
3.01 to 3.5 (L) 33 36 0.04 1.11 1.27 0.04
3.51 to 4.0 (L) 34 36 0.09 1.17 1.22 0.08
4.01 or more (L) 34 38 <0.01 1.20 1.32 0.01
*all p-value reported refers to Mann-Whitney U test. 
Sensitivity analyses: Adverse maternal outcome & coagulation parameters aPTT- ratio. Laboratory parameters 
are presented in box plots.  Circles are outliers. The box represents the 25th and 75th percentiles and the whiskers 
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FLUID MANAGEMENT AND DILUTIONAL COAGULOPATHY IN SEVERE POSTPARTUM HAEMORRHAGE
Abstract
Background: The view that 2 litres of crystalloid and 1.5 litres of colloid can be infused 
while awaiting compatible blood for patients with major postpartum haemorrhage 
is based on expert opinion documents. We describe real-world changes in levels of 
coagulation parameters after the administration of different volumes of clear fluids to 
women suffering from major postpartum haemorrhage.  
Methods: We performed a nationwide retrospective cohort study in the Netherlands 
among 1038 women experiencing severe postpartum haemorrhage who had received 
at least four units of red cells or fresh frozen plasma or platelets in addition to red cells. 
The volume of clear fluids administered before the time of blood sampling was classified 
into three fluid administration strategies, based on the RCOG guideline: < 2L, 2-3.5L and 
> 3.5L. Outcomes included haemoglobin, haematocrit, platelet count, fibrinogen, aPTT 
and PT levels. 
Results: Haemoglobin, haematocrit, platelet count, fibrinogen and aPTT were associated 
with volumes of clear fluids, which was most pronounced early during the course of 
postpartum haemorrhage. During the earliest phases of postpartum haemorrhage 
median haemoglobin level was 10.1 g/dl (IQR 8.5-11.6) among the women who received 
< 2 L clear fluids and  8.1 g/dl (IQR 7.1-8.4) among women who received > 3.5 L of clear 
fluids; similarly median platelet counts were 181 x109/litre (IQR 131-239) and 89 x109/litre 
(IQR 84-135), aPTT 29s (IQR 27-33) and 38s (IQR 35-55) and fibrinogen 3.9 g/L (IQR 2.5-5.2) 
and 1.6 g/L (IQR 1.3-2.1). 
Conclusions: In this large cohort of women with severe postpartum haemorrhage, 
administration of larger volumes of clear fluids was associated with more severe 
deterioration of coagulation parameters corresponding to dilution. Our findings 
provide thus far the best available evidence to support expert opinion-based guidelines 
recommending restrictive fluid resuscitation in women experiencing postpartum 
haemorrhage. 
Background
Postpartum haemorrhage continues to be a leading cause of maternal health problems 
worldwide1. Depending on the primary cause of haemorrhage, acquired coagulopathy 
may develop during the course of postpartum haemorrhage and aggravate bleeding2. 
Rapid intravenous infusion of clear (crystalloid and colloid) fluids is generally applied 
during on-going haemorrhage to establish haemodynamic stability, restore adequate 
intravascular volume and improve oxygen carrying capacity and oxygen tissue delivery3. 
When given in large volumes, clear fluids initiate dilution of clotting factors resulting in 
impairment of coagulation and coagulopathy4-6. On top of that, rapid consumption of 
fibrinogen, clotting factors and platelets as a result of persistent blood loss, aggravates 
coagulopathy5. The use of colloid fluids has proven to negatively influence coagulation 
capacity and endothelial function7,8. These findings have led to less aggressive fluid 
management in patients with traumatic haemorrhagic shock9. 
International guidelines on management of women with severe postpartum haemorrhage 
elucidate the lack of quantitative evidence on the effect of different fluid management 
strategies on parameters of coagulopathy. For instance, the RCOG green-top guideline 
advises to follow the expert opinion-based recommendation to administer up to 3.5 
litres of warmed clear fluids, starting with 2 litres of warmed isotonic crystalloids until 
blood products are available in case of persistent postpartum blood loss exceeding 1000 
ml10.  The experts formed their opinions based on experiments in laboratories, animals, 
healthy volunteers, and observations from trauma patients. However, findings from these 
studies may not apply to pregnant women, since pregnancy induces haemodynamic and 
haematologic changes that protect them against haemorrhage during birth. Maternal 
blood volume increases between 1.2 and 1.6 litres above non-pregnant values, creating 
a hypervolemic state during pregnancy4. To enable evidence-based recommendations 
on fluid management strategies in women with major postpartum haemorrhage, 
more insight is needed on the changes of coagulation parameters after administration 
of different volumes of fluids4. To the best of our knowledge no previous studies have 
been conducted into different fluid management strategies and their possible effect on 
coagulation parameters in women experiencing postpartum haemorrhage.   
The aim of this study was to describe the association between administration of different 
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Methods
Design and study population
We studied volumes of clear fluids and results of coagulation parameter measurements 
during postpartum haemorrhage in a cohort of women who had been included in a 
nationwide retrospective cohort study in 61 hospitals in the Netherlands, the TeMpOH-1 
(Transfusion strategies in women during Major Obstetric Haemorrhage) study. Included 
in the TeMpOH-1 study were women who received at least four units of red cells or any 
transfusion of fresh frozen plasma (FFP) and/or platelets in addition to red cells because 
of obstetric haemorrhage defined as ≥1000 mL blood loss during pregnancy, childbirth 
or puerperium between January 1st, 2011 and January 1st, 2013. For the present 
analyses, we selected women from the TeMpOH-1 cohort who met criteria for primary 
postpartum haemorrhage: any amount of blood loss exceeding 1000mL within the first 24 
hours after childbirth. Women with no coagulation parameters measured during active 
postpartum haemorrhage and women with missing data on volumes and timing of clear 
fluids were excluded. In case transfusion of blood products occurred before onset of 
clear fluid administration, patients were also excluded.  The Ethical Committee of Leiden 
University Medical Centre (P12.273) and the institutional review boards of all participating 
hospitals approved of the study. The study was registered in the Netherlands Trial Register 
(NTR4079). Details regarding study design have been reported elsewhere11. The need to 
obtain informed consent was waived by the ethics committee because of the retrospective 
design. Women 18 years of age and older who met the inclusion criteria were selected. 
Data collection
To identify all consecutive women who had been transfused with the aforementioned 
amount of blood products because of postpartum haemorrhage in the participating 
hospitals, data from the hospitals’ blood transfusion services were merged with data from 
birth registers of contributing hospitals. Qualified medical students and research nurses 
collected routine data from the medical records with regard to (obstetric) history and 
course of the current pregnancy, as well as data pertaining to characteristics of participating 
women, mode of birth, primary cause of haemorrhage, placentation, characteristics of 
shock (defined as systolic blood pressure < 90 mmHg or heartrate > 120 bpm), surgical 
and haemostatic interventions to stop bleeding and coagulation parameters. Results 
of all measurements of haemoglobin level (Hb, g/dl), haematocrit (Ht, fraction), platelet 
count (x109/litre), activated partial thromboplastin time (aPTT, seconds), prothrombin 
time (PT, seconds) and fibrinogen (g/L) levels from the first measurement of blood loss 
onwards were documented; this included parameters drawn from cases before they had 
bled a total volume of 1000mL. Outliers of levels of coagulation parameters were verified 
in the medical records. In addition, detailed information on crystalloid and colloid fluids 
administered during the course of postpartum haemorrhage was collected: total volume 
and type of clear fluids given, as well as timing information with regard to onset and end 
of infusion. Information on timing and volume of repetitive blood loss measurements was 
also retrieved from the medical files. In most cases blood loss was measured by weighing 
soaked gauzes during and after birth and by use of a collector bag and suction system in 
the operating theatre. 
Severe acute maternal morbidity and maternal mortality 
The composite endpoint severe acute maternal morbidity and mortality comprised 
emergency peripartum hysterectomy, ligation of the uterine arteries, B-Lynch suture (in 
the Netherlands only used as emergency procedure), arterial embolization or admission 
into an intensive care unit.
Statistical analyses
The aim was to describe values of measured laboratory parameters according to increasing 
“volume of blood loss” and “volume of clear fluids administered” during the course of 
severe postpartum haemorrhage. In order to have an estimate of the “volume of blood 
loss” and of “volume of clear fluids administered” for all blood samples (and their respective 
laboratory results) we used linear interpolation of the actual measurement of “volume of 
blood loss” and “volume of clear fluids administered” before and after each blood sample. 
The volume of blood loss at the time of blood sampling was categorised in 8 groups: 0-1.0L, 
1.0-1.5L, 1.5-2.0L, 2.0-2.5L, 2.5-3.0L, 3.0-3.5L, 3.5-4.0L and >4.0L. Coagulation parameters 
were allocated to the category representing the volume of blood loss at sampling. In case 
of multiple laboratory measurements per patient within one blood loss category, the 
mean of the values was used in the analyses, calculating a patient just once per category. 
Subsequently, within these blood loss categories, the volume of clear fluids administered 
at the time of blood sampling was calculated and classified into three fluid administration 
strategies: < 2.0L, 2.0-3.5L and > 3.5L. These three administration strategies were based 
on the RCOG green-top guideline, which recommends to administer up to 3.5 litres of 
warmed clear fluids, starting with 2 litres of warmed isotonic crystalloids if blood is not 
available[10] . Since blood sampling during postpartum haemorrhage was not performed 
at predefined time points and samples were obtained on request of the physician on 
call during postpartum haemorrhage, patients could have different frequencies and 
panels of coagulation parameters. Reference ranges of aPTT varied somewhat for the 
61 participating hospitals as a result of use of different types of reagents. Therefore, an 
aPTT ratio was calculated by dividing the aPTT level of cases by the mean of the hospital 
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Results
Patient characteristics
A total of 1038 women with severe postpartum haemorrhage had at least one valid 
measurement of coagulation parameters sampled during active bleeding in addition to 
data on volume and timing of clear fluids administered (Figure 1). Baseline characteristics 
are reported in Table 1. Women were on average 31 years of age, gave birth at a median 
gestational age of 39.7 weeks and 25% delivered by caesarean section. Uterine atony 
was the primary cause of bleeding in 66% of the cases and 34% of women developed a 
composite endpoint of severe acute maternal morbidity or mortality. The median total 
volume of blood loss among all 1038 women with postpartum haemorrhage was 3.0 L 
(interquartile range 2.5-4.0).  In our cohort, women in the lowest fluid categories showed 
fewer signs of shock and were administered fewer blood products when compared to 
women in the other fluid categories for all coagulation parameters (data presented in table 
adjacent to Figure 3). 
Figure 1.  Inclusion flowchart for ‘fluid management and dilutional   
  coagulopathy in severe postpartum haemorrhage: a nationwide   
  retrospective cohort study’
N= 191.772  
women giving birth in 61 
participating hospitals in 
The Netherlands from 
2011-2013 
N= 1391 (0.73%)  
women received ≥ 4 units of red cells 
or any transfusion of FFP or platelets 
in addition to red cells because of 
postpartum haemorrhage 
N= 1038 (0.54%) 
Women with at least one valid 
measurement of coagulation 
parameters sampled during active 
bleeding and full data available on 
volume and timing of clear fluids 
 
Cross-referencing data  
of hospitals’ blood 
transfusion services 
with local birth registers 
 
Table 1.  Clinical characteristics of the cohort of 1038 women with ongoing  
  postpartum haemorrhage included in this analysis
Patients n=1038
Maternal characteristics 
      Age (years)   31.0 (28.0-35.0) *
      BMI (kg/m2) 23.2 (21.0-26.3)
      Ethnicity Caucasian 747 (72%)†
      Nulliparity   534 (51%)
      Gestational age 39.7 (38.1-40.7)
Mode of birth
      Caesarean section 254 (24%)
      Vaginal 780 (75%)
Comorbidity
      Pre-eclampsia/ HELLP 104 (10%)
      Anti-coagulant use 6 (0.6%)
Transfer to hospital
      No transfer (birth in hospital) 753 (73%)
      Transfer to hospital during labour 157 (15%)
      Postpartum transfer (birth at home) 128 (12%)
Primary cause of bleeding
     Uterine atony 684 (66%)
     Retained placenta 168 (16%)
     Pathological ingrowth of placenta 89 (9%)
     Surgical bleeding and abruption/coagulopathy 97( 9%)
Placentation
     Abnormal localisation placenta 65 (6%)
     Pathological ingrowth placenta 97 (9%)
Composite endpoint severe maternal morbidity and mortality 355 (34%)
     Embolisation 124 (12%)
     Hysterectomy 57 (5%)
     Emergency B-Lynch 27 (3%)
     Ligation arteries 7 (0.7%)
     ICU admission 295 (28%)
     Maternal mortality 6 (0.6%)
Haemostatic interventions
     Fibrinogen administered 98 (9%)
     Tranexamic acid administered 473 (46%)




































































































































































































































































































































































































































































































     Bleeding rate  (ml/min) ‡ 2.4 (1.3-4.8)
     Shock 927 (89%)
     Total volume blood loss (L) 3.0 (2.5-4.0)
     Total volume of clear fluids (L) 3.0 (2.0-4.0)
     Total units of blood products (n) 6.0 (4.0-8.0)
 * Values are presented as median with (interquartile range), † percentage, ‡ maximum
Volume expansion and volume of blood loss
Figure 2 presents volumes of blood loss and volumes of infused fluids. Among women 
who had one or more laboratory parameters measured during the first phases of 
postpartum haemorrhage (n=245 for 0 to 1L; n=306 for 1 to 1.5L; and n=351 for 1.5 to 2L) 
the mean volume of replacement therapy (clear fluids and blood products) administered 
was less or equal the total volume of blood loss. During the next phases of postpartum 
haemorrhage (blood loss between 2-2.5L) the mean volume of replacement therapy 
(clear fluids and blood products) was higher than the volume of blood loss. This “overload” 
enlarged with increasing blood loss volumes, reaching 32% more volume replacement 
compared to blood loss in the phase in which the women had lost 3.5-4L (5.3L infused /4 
L lost). For all categories of blood loss, mean volume of clear fluids administered did not 
exceed and in most cases was similar to the maximum blood loss. With increasing blood 
loss, the proportion of blood products (versus clear fluids) administered showed a gradual 
increase, from 118/1178mL (10%) at 1000-1500mL blood loss to 1605/5279mL (30%) after 
blood loss up to 4000mL. 
Laboratory parameters after different volumes of clear fluids in the course of 
postpartum haemorrhage
Figure 3 presents results of laboratory tests according to received volumes of clear fluids (0 
to 2 L, 2 to 3.5 L or more than 3.5 L) during the first two litres of postpartum haemorrhage. 
From 1031 women a total of 2714 haemoglobin measurements were available. 
Administration of higher volumes of clear fluids was associated with lower haemoglobin 
and haematocrit levels and this was most pronounced in the earlier phases of postpartum 
haemorrhage (Figure 3 and supplemental table S1 and figure S2). For example, when the 
women had lost less than 1.0 L of blood, the median haemoglobin level was 10.1 g/dl (IQR 
8.5-11.6) if they had received < 2.0 L of clear fluids, whereas after receiving 2.0 – 3.5 L clear 
fluids median haemoglobin was 8.4g/dl (IQR 6.4-9.7).  
 
Continuing  Table 1. Clinical characteristics of the cohort of 1038 women with  
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Figure 3.  Coagulation parameters according to clear fluid administration   
  (0-2L, 2L-3.5L, >3.5L) and increasing volume of blood loss 
  (0-1.0, 1.0-1.5, 1.5-2.0 L). 
Legend: Laboratory parameters are presented in box plots.  Circles are outliers. The box represents the 25th and 
75th percentiles and the whiskers are the upper and lower adjacent values. 
*Statistics: (1) Patient count; (2) Percentage of women who received blood products; (3) Percentage of women 
who  experienced shock surrounding blood sampling; (4) mean bleeding rate in ml/min surrounding blood 
sampling.
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Platelet counts of 804 women decreased over the three increasing fluid administration 
categories. In samples drawn in the earliest phase of postpartum haemorrhage (0-1L 
blood loss), median platelet counts were 181 (IQR 131-239), 154 (IQR 99-205) and 89 x109/
litre (IQR 84-135) in the three categories of increasing volumes of fluids administered. A 
similar pattern was observed in consecutive blood loss categories.
Fibrinogen measurements of 438 women were available for analyses. Administering 
higher volumes of clear fluids was associated with a decreasing level of fibrinogen in 
measurements in the early phases of postpartum haemorrhage (up to 2L of blood loss). 
The largest change was displayed for measurements performed in the earliest phase of 
postpartum haemorrhage (blood loss 0-1000mL): 3.9 g/L (IQR 2.5-5.2), 2.6 g/L (IQR 1.6-
3.7), 1.6 g/L (IQR 1.3-2.1) over the three fluid management categories. 
PT and aPTT were longer after administration of larger volumes of clear fluids. For both, 
the largest difference was observed between measurements in the most restrictive fluids 
category (<2L) and the most liberal category (>3.5L). In samples drawn between 0-1L 
blood loss, PT was 13 (IQR 11-15) and 17 seconds (IQR 12-19) and aPTT 29 (IQR 27-33) and 
38 seconds (IQR 35-55) in lowest and highest fluid administration categories respectively. 
Levels of PT and aPTT of women administered 2-3.5L of fluids were similar to blood 
samples of women who were administered less than 2L of fluids. Results of the aPTT ratio 
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Discussion
This nationwide retrospective multicentre cohort study describes coagulation parameters 
after administering different volumes of resuscitation fluids in 1038 women with ongoing 
severe postpartum haemorrhage. The administration of larger volumes of clear fluids 
was associated with deterioration of levels of haemoglobin, haematocrit, platelet count, 
fibrinogen, aPTT and PT which was most pronounced during the earlier phases of 
postpartum haemorrhage. 
Strengths and limitations of our study
A strength of the study is that we included a large cohort of women who had suffered severe 
postpartum haemorrhage and who had been treated with different volume replacement 
strategies. Women in our study were categorised based on similar volumes of blood loss 
at time of blood sampling, thereby making them comparable on a clinical level during 
the course of haemorrhage. Volume replacement had been carefully documented in the 
medical files in all the participating hospitals ensuring correct classification of women 
according to the different replacement strategies. Both these strengths allow for reliable 
description of abnormalities in coagulation in relation to volume replacement therapy. 
We stratified our findings according to volume of blood loss. Volume of blood loss was 
measured in most cases by weighing soaked gauzes during and after birth and by use of a 
collector bag and suction system in the operating theatre, in addition to visual estimation. 
Thus, there may be misclassification of volume of blood loss in both directions, over- and 
underestimation and it is therefore difficult to know whether and how our findings are 
affected by this misclassification. Our findings are also affected by the fact that inherently 
more blood samples are drawn from women with more severe bleeding. This may have 
led to overestimation of the number of women with abnormal laboratory test results. 
Because of the design of the study we did not have influence on the number and specific 
panels of coagulation samples requested. Therefore, our results show different selections 
of women in all blood loss categories that we present. Although it is tempting to infer 
that high volumes of clear fluids are causally related to the observed dilution our study 
does not allow such inference. There are many other factors that may have influenced 
coagulation parameters such as the primary cause of haemorrhage, bleeding and 
treatment characteristics and the presence of comorbidities. This descriptive study 
does not allow for disentanglement of the separate effects of these joint risk factors. We 
excluded 353 women because they had no valid lab measurement available during active 
bleeding or data were missing on volume or timing of clear fluids administered. To be 
certain their exclusion did not induce a systemic error to our data resulting from selection 
bias, we compared these women on the most relevant table 1 items: mode of birth, 
nulliparity, primary cause of haemorrhage, the composite endpoint of severe maternal 
morbidity and mortality, bleeding rate at sampling, presence of shock and total volume of 
blood loss. No differences were observed compared to the women that were included in 
the study, ruling out the presence of a systemic error influencing the results.
Comparison with other studies
To the best of our knowledge no previous studies have described the association between 
different fluid management strategies and coagulation parameters during the various 
phases of severe postpartum haemorrhage. Yet, our findings corroborate results of 
previous studies into the effect of dilution on coagulation parameters. An in vitro study 
evaluating the effect of haemodilution on coagulation factors found that PT and aPTT were 
significantly prolonged after 60% and 80% dilution12. Another in vitro study investigated 
the effect of haemodilution on the course of global coagulation tests and clotting factors. 
Levels of dilution-dependent coagulation factors and aPTT were found to decrease in 
an almost linear manner. Critically low activities for coagulation factors and a critically 
low level of fibrinogen were measured at dilutions of between 60% and 75%13. An in vivo 
study reported coagulation parameters in hypotensive patients with penetrating torso 
injuries who were treated with immediate versus delayed fluid resuscitation. Patients in 
the immediate fluid administration group showed worse levels of haemoglobin, platelet 
count, PT and APTT compared to patients in the delayed fluid administration group14. 
No previous studies were found that examined the change in coagulation parameters 
as a result of different fluid management strategies in women experiencing postpartum 
haemorrhage.  
Clinical implications
In our cohort of women experiencing postpartum haemorrhage, we displayed changes 
occurring on coagulation parameter level after administering different volumes of 
fluids. Administration of larger volumes of clear fluids was associated with more severe 
worsening of levels of haemoglobin, haematocrit, platelet count, fibrinogen, aPTT and 
PT which was most pronounced during the earlier phases of postpartum haemorrhage. 
Our findings provide quantitative evidence to reinforce expert opinion-based 
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Conclusions
In this nationwide retrospective cohort study in 1038 women on the change in coagulation 
parameters with increasing volumes administered during the course of postpartum 
haemorrhage necessitating blood transfusion, the administration of large volumes of 
clear fluids was associated with changes in coagulation parameters corresponding to 
dilutional coagulopathy.  Our findings provide thus far the best available evidence to 
support expert opinion-based guidelines recommending restrictive fluid resuscitation in 
women experiencing postpartum haemorrhage.
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Supplemental material
S1  Patient count, mean, sd, median and IQR for coagulation parameters in addition to 
Figure 3
S2   Coagulation parameters according to clear fluid administration (0-2L, 2L-3.5L, 
>3.5L) and increasing volume of blood loss (0-1.0, 1.0-1.5, 1.5-2.0 L, 2.0-2.5L, 2.5-
3.0L, 3.0-3.5L, 3.5-4.0L and >4L). 
S3  aPTT ratio according to clear fluid administration (0-2000mL, 2000mL-3500mL, 






































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































S2   Coagulation parameters according to clear fluid administration (0-2L, 
2L-3.5L, >3.5L) and increasing volume of blood loss (0-1.0, 1.0-1.5, 1.5-2.0 L, 
2.0-2.5L, 2.5-3.0L, 3.0-3.5L, 3.5-4.0L and >4L). 
Laboratory parameters are presented in box plots.  Circles are outliers. The box represents the 25th and 75th 
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S3  aPTT ratio according to clear fluid administration (0-2000mL, 2000mL-
3500mL, >3500mL) and increasing blood loss (0-1.0, 1.0-1.5, 1.5-2.0, 2.0-
2.5l)
*Statistics: (1) Patient count; (2) Percentage of women who received blood products; (3) Percentage of women 







 COMPARISON OF ROTEM DELTA AND SIGMA DURING POSTPARTUM HAEMORRHAGE
Abstract
Background: Haemostatic treatment in women experiencing postpartum haemorrhage 
is increasingly based on point-of-care devices such as ROTEM® thromboelastometry. 
Recently, the ROTEM® Sigma was introduced, a fully automated successor of the ROTEM® 
Delta device. To determine whether these devices provide similar results, we compared 
ROTEM® parameters using the ROTEM Delta and Sigma devices in women experiencing 
postpartum haemorrhage. 
Methods: Prospective observational cohort study of 23 women experiencing postpartum 
haemorrhage.  ROTEM® INTEM, EXTEM, FIBTEM and APTEM measurements handled by 
the ROTEM® Delta and Sigma devices were compared. ROTEM® FIBTEM values were also 
related to Clauss fibrinogen values.
Results: A correlation of Spearman’s r  (rs) varying between 0.76 and 0.95 was displayed 
between A5, A10 and A20 measured by EXTEM, INTEM and APTEM assays executed on 
both devices; A5, A10 and A20 of FIBTEM correlated less well (rS between 0.71 and 0.74), 
especially after five and ten minutes. Correlation between both devices regarding clotting 
time (CT) was poor. The observed correlation between levels of Clauss fibrinogen and 
FIBTEM A5 was rs = 0.70, (95% confidence interval (CI): 0.38 to 0.87)  for Delta and rs = 0.85, 
(CI 0.65 to 0.94)  for Sigma.
Conclusion: A5, A10 and A20 measured in EXTEM, INTEM and APTEM obtained from 
ROTEM® Delta and Sigma devices were similar. EXTEM, FIBTEM and APTEM CT values from 
both devices showed no correlation. Substantial variation was found between FIBTEM 
assays of the devices. Consequently, results of FIBTEM assays should always be interpreted 
in the context of device-specific reference values. Correlation with Clauss fibrinogen was 
better in the ROTEM® Sigma device.
Introduction
Postpartum haemorrhage continues to be one of the leading causes of maternal 
morbidity and mortality worldwide1. By close monitoring of haemostasis, abnormalities 
in coagulation parameters may be detected soon after onset of bleeding. This could 
contribute to more individually targeted haemostatic therapy for women experiencing 
postpartum haemorrhage, potentially leading to better maternal outcomes2. Some 
have suggested that a low fibrinogen concentration might be the earliest predictor of 
progression towards severe postpartum haemorrhage3-6.  Due to long turn-around times 
of traditional coagulation parameters like Clauss fibrinogen, their clinical applicability 
in presence of rapid bleeding is limited. For early detection of changes in coagulation 
parameters, point-of-care devices using a visco-elastometric method for haemostasis 
testing like ROTEM® thromboelastometry can be used. Several studies conducted in 
women during postpartum haemorrhage have confirmed that the ROTEM® FIBTEM A5 
assay, available 7 to 10 minutes after sampling, provides an indication of the concentration 
of fibrinogen during postpartum haemorrhage2,5,7. 
Until recently, the ROTEM® Delta device was the most common device to conduct 
thromboelastometry. To retrieve quick information on the coagulation status of a woman, 
users combine blood samples with reagents in several pipetting steps. Although this 
procedure is relatively user-friendly and the device is marketed as a point-of-care device, 
the procedure can be quite complicated for non-laboratory trained personnel. Now, the 
Werfen® company has introduced a fully automated successor of the ROTEM® Delta device, 
the Sigma. The fact that with this device there is no need for a pipetting procedure, makes 
it more applicable as a point-of-care device to be used at the bedside. We performed local 
validation of the new device. To the best of our knowledge no data have been published 
on comparability of measurements performed on the ROTEM® Delta and ROTEM® Sigma 
device. 
The aim of this study was to compare ROTEM® EXTEM, INTEM, FIBTEM and APTEM 
measurements conducted by the ROTEM® Delta and Sigma devices in women experiencing 
postpartum haemorrhage. Moreover, ROTEM® FIBTEM values obtained from both devices 
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Materials and methods
Design and study population
We studied women who had been included in the TeMpOH-2 (Towards better Prognostic 
and Diagnostic strategies for Major Obstetric Haemorrhage) study, a prospective cohort 
of pregnant women in the Netherlands between February 2015 and April 2018. Blood 
samples were drawn from women experiencing postpartum haemorrhage (blood loss ≥ 
1000 mL). Up to three samples per woman were available, with the first sample drawn at a 
volume of blood loss between 800-1500 mL. Subsequent samples were drawn in case of an 
additional volume of blood loss of 1000-1500mL. Besides ROTEM® assays INTEM, EXTEM, 
FIBTEM and APTEM, fibrinogen concentration was assessed by the Clauss method. During 
the inclusion period of the TeMpOH-2 study, the ROTEM® Sigma device was launched 
onto the market. Subsequently, in one of the study sites measurements were performed 
simultaneously on both devices between July 2017 and April 2018 to study whether the 
devices yielded similar results. Data regarding maternal age, BMI, ethnicity, gestational 
age at birth, mode of birth, primary cause of haemorrhage and total volume of blood loss 
were recorded from medical files available at the maternity ward and operating theatre. 
Approval for the study was obtained from the Ethical Committee of the Leiden University 
Medical Centre (P13.246). The study was registered at ClinicalTrials.gov (NCT02149472). 
Written informed consent was obtained from all women participating in the study. 
Women below 18 years of age or with a gestational age below 24 weeks at the time of 
birth were excluded. Women with coagulation disorders or who used anticoagulants were 
not excluded. 
Handling of ROTEM® devices and measurements
Both the ROTEM® Delta and Sigma device were positioned in a utility room equipped to 
locate laboratory devices at the maternity ward. ROTEM® measurements were performed 
by well-trained study personnel including research nurses and clinical midwives. In case 
measurements could not be started immediately, citrated blood samples were stored and 
handled at 37ºC. Results were only taken into consideration when measurements had 
started within 4 hours after blood sampling as sample stability up to 4-6 hours has been 
confirmed in previous studies [8,9]. Blood withdrawal was performed by venepuncture 
using a 21 gauge blood collection needle or following insertion of a peripheral vein 
cannulation. Blood was collected in vacuum tubes (BD Vacutainer® Citrate tubes 3.2% 
and BD Vacutainer® spray-coated K2EDTA tubes), always discarding the first 3 mL of blood. 
Citrated tubes were collected before EDTA tubes. Visual inspection was conducted to 
verify if the minimum acquired volume of blood was collected, otherwise the tube was 
discarded. The citrated tubes for ROTEM analyses were handled at the maternity ward, 
whereas tubes containing blood for other coagulation parameters were send to the 
laboratory by pneumatic tube system transport. Blood samples for Clauss fibrinogen 
assays were handled immediately after arriving at the laboratory and centrifuged for 10 
minutes at 2700g  at a temperature of 20ºC.  External quality control for Clauss fibrinogen, 
APTT and PT was secured by participation in the international External Quality Assessment 
Programme (EQAP).  Internal quality control was performed weekly by using the quality 
control reagents ‘ROTROL N’ (normal control)  and ‘ROTROL P’ (abnormal control) provided 
by the manufacturer. Also, daily, quarterly and yearly maintenance on the devices was 
carried out according to the manufacturer’s instructions.  Single use reagents were used 
in the ROTEM® Delta device. 
ROTEM®  measurements
The ROTEM® Delta and Sigma analyses were performed according to the instructions 
provided by the manufacturer resulting in a visual display of the coagulation process 
(Figure 1). Parameters considered include clotting time (CT) in seconds and amplitudes 
of clot firmness measured in millimetres at 5 (A5), 10 (A10) and 20 (A20) minutes after 
start of clot formation including maximum clot firmness (MCF). The following reagents 
were used: EXTEM to activate the extrinsic coagulation pathway, INTEM to analyse the 
intrinsic part of the coagulation cascade, FIBTEM to provide an indication of the fibrinogen 
concentration and APTEM to detect hyperfibrinolysis. All measurements on the ROTEM 
Delta® device were conducted with single use reagent. On the ROTEM® Sigma device, 
the same measurements can be performed in a fully automated manner: a citrated tube 
with whole blood is inserted into a cartridge holding balls containing the four different 
reagents, which is then entered into the device initiating the measurements. 
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Statistical analyses
Characteristics of the women included are reported using descriptive statistics. 
Coagulation parameters are presented as median and interquartile ranges because of 
their non-Gaussian distribution. Non-Gaussian distribution was established by graphical 
visualisation and confirmed via Kolmogorov-Smirnov test. All ROTEM® parameters were 
verified by visually inspecting their corresponding temograms for normal lay-out and 
by checking all parameters for error codes. Unlikely values were excluded from the 
analyses.  We first calculated the differences between values of ROTEM® parameters CT, 
A5, A10, A20 and maximum clot firmness (MCF) from the same samples on each of the two 
devices. Since the ROTEM® Sigma device was newly launched, the Delta was considered 
the reference.  Statistical significance of the differences between the results from the 
two devices was tested with the Wilcoxon signed rank test. We also assessed Spearman’s 
rank correlation coefficients of ROTEM® Sigma and Delta results (rs) and for the correlation 
between ROTEM® FIBTEM values of both devices and fibrinogen concentration as obtained 
by the Clauss assay10. 
Results
Characteristics of the women included
During the inclusion period of this sub-study of the TeMpOH-2 study, samples of 23 
women experiencing postpartum haemorrhage were analysed, simultaneously in both 
ROTEM® devices. Baseline characteristics of the study population are reported in Table 1. 
Women were on average 35 years of age (interquartile range (IQR) 31 to 38), gave birth at 
a median gestational age of 39 weeks (IQR 37.4 to 39.3) and in 43% (10/23) by caesarean 
section. Median total volume of blood loss was 1400 mL (IQR 1200 to 1800). One sample 
was available for 23 women, and a second sample for three women. For EXTEM and INTEM 
assays, 26 valid measurements executed on both devices were available. For FIBTEM and 
APTEM assays, 23 and 25 valid combinations of measurements could be obtained. Of the 
total of 26 measurements, three FIBTEM and one APTEM measurement had to be excluded 
because of measurement errors, providing no valid result. Clauss fibrinogen assays were 
available for 21 women, with a median value of 4.3 (IQR 4.1 to 4.8).  
 
Table 1.  Characteristics of the women included
Patients n=23
Maternal characteristics 
Age in years   35 (31 to 38)*
BMI in kg/m2 23 (21 to 28)
Ethnicity, Caucasian 17 (74%)
Gestational age in weeks 39.0 (37.4 to 39.3)
Mode of birth
Caesarean section 10 (43) †
Vaginal 13 (57)
Primary cause of bleeding
Uterine atony 7 (30)
Retained placenta 8 (35)
Surgical bleeding 6 (26)
Genital tract trauma 1 (4)
Placental abruption 1 (4)
Pathological ingrowth of placenta/placenta praevia/uterine rupture/
coagulopathy    
-
Bleeding characteristics
Total volume blood loss in mL 1400 (1200 to 1800)
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EXTEM 
Median difference between both devices for EXTEM CT was -6.5 seconds (IQR -9.25 to 
-1.75) with a poor Spearman’s correlation coefficient, rs = 0.18 (Figure 2, Table 2 and S1). 
Median differences between amplitudes at 5 (A5), 10 (A10) and 20 (A20) minutes and MCF 
were minor and statistically non-significant: -1.5 mm(IQR -3.25 to 2.0), 0.5mm (IQR -1.0 
to 1.25), 0.0mm (IQR -1.25 to 1.25) and -0.5mm (-2.25 to 1.0) respectively; corresponding 
Spearman’s correlation coefficients were excellent (Table 3). 
INTEM 
INTEM values showed a median difference in CT between devices of +3.5 seconds (IQR 
-2.0 to 7.0), Spearman’s rs = 0.86. Differences between amplitudes diminished over time: 
+2.0mm (IQR 1.0 to 3.0) after 5 (A5) and 10 (A10) minutes, and +1mm (IQR 0.0 to 2.0) at 
20 (A20) minutes and MCF, with excellent Spearman’s correlation coefficients.  Although 
the absolute differences between amplitudes were relatively small, these were statistically 
significant.
FIBTEM
The median FIBTEM CT value, performed on the ROTEM® Delta device, was 6 seconds (IQR 
-1 to -10) lower when compared to the values of the Sigma, rs = 0.42. This difference was 
also displayed in the amplitudes at 5, 10 and 20 minutes where some stabilisation occurred 
over time: A5 -4.0mm (IQR -5.0 to -2.0), A10 -3mm (IQR -3.0 to -1.0) and A20 -2mm (IQR -3.0 
to -1.0). The differences at A5 and A10, relevant for acute clinical decision making, were 
statistically significant. Spearman’s correlation coefficients for all FIBTEM measurements 
were only moderate compared to the results from the other assays, reflecting substantial 
variation between measurements. 
APTEM
Variation between APTEM CT values on both devices was large, with a very poor 
Spearman’s correlation coefficient of -0.09. Median differences between amplitudes over 
time were small, but did show variation over time: A5 0.0mm(IQR -1.0 to 3.0), A10 2.0mm 
(IQR 1.0 to 4.0), A20 2.0mm (IQR 0.5 to 2.5) and MCF 0.0mm (IQR -1.0 to 2.0).  
Correlation between Clauss fibrinogen and ROTEM® FIBTEM parameters 
To determine the correlation between fibrinogen concentration measured according 
to Clauss and ROTEM® FIBTEM parameters A5, A10, A20 and MCF, these values were 
compared for both devices. Spearman’s correlation coefficients for fibrinogen and FIBTEM 
A5 samples were r = 0.70, (95% CI: 0.377 to 0.867) for the Delta device and r=0.85, (95% CI: 
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A positive correlation was found for MCF, A5, A10 and A20 measured by ROTEM® assays 
EXTEM, INTEM and APTEM, executed on both the ROTEM® Delta and Sigma device in 
women experiencing postpartum haemorrhage. FIBTEM parameters however, showed 
rather wide variation, and only moderate correlation.  Moreover, statistically significant 
differences were found between devices at A5 and A10, the most relevant parameters 
for acute clinical decision making. FIBTEM measurements from both devices showed 
moderate to good correlation with Clauss fibrinogen concentration, with a better result 
for the Sigma device.
Strength and limitations of this study
A strength of our study is that we were able to prospectively study ROTEM® measurements 
performed in women experiencing postpartum haemorrhage. Samples were handled 
on ROTEM® Delta and Sigma devices simultaneously and were not only compared to 
each other but also to the traditional Clauss fibrinogen assay. A limitation of our study 
is the small sample size, specifically a limited number of low fibrinogen concentrations. 
Since low fibrinogen concentrations represent women who are potentially in need of a 
haemostatic intervention, it is of high importance to also assess validity of samples in 
women with low fibrinogen concentrations. 
Interpretation of results
The ability to perform point-of-care coagulation tests  in acutely bleeding patients 
potentially provides a considerable clinical advantage. Yet, specifically in an acute situation, 
reliability of measurements is of utmost importance. For EXTEM, INTEM and APTEM 
assays, comparability was found to be excellent between both devices. This confirms the 
reliability of our measurements and study procedures.    However, a statistically significant 
difference was found between FIBTEM measurements A5 and A10, the most relevant 
parameters for acute clinical decision making. For example, the use of an algorithm based 
on FIBTEM A5 on a Delta device will tend to provide a lower result for a given Clauss 
fibrinogen value. This will result in overtreatment and unnecessary interventions in case 
this difference remains unrecognized and the algorithm is not amended to account for 
this device specific difference. Consequently we can conclude that the two devices are not 
directly interchangeable and intervention points for algorithms must be tailored to the 
device used.    When looking at the performance of both devices in our cohort of women 
experiencing postpartum haemorrhage, we did observe a better correlation with Clauss 
fibrinogen in the ROTEM® Sigma device (rs range 0.82-0.86) as compared to the Delta (rs 
range 0.66-0.70). 
Figure 2.  Scatterplots and Spearman’s correlation coefficients (rs) for EXTEM,  
  INTEM, FIBTEM and APTEM parameters measured on ROTEM® Delta 
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The question that remains unanswered is why this effect is only observed in FIBTEM 
measurements and not in EXTEM, INTEM and APTEM. Potentially, the absence of platelets 
in the FIBTEM assay, resulting in lower amplitudes when compared to the other assays 
increases the sensitivity of the FIBTEM measurement. This finding needs further evaluation 
because of its high importance to clinical practice with the use of practice flow-charts using 
exact FIBTEM cut-off points to initiate (haemostatic) treatments.  
Very poor correlation between CT measured on both devices was observed for EXTEM, 
FIBTEM and APTEM assays. Correlation for INTEM CT however, was strong. A new mode of 
presenting the reagent (a ball constituted of reagent, located at the bottom of the cartridge) 
on top of a rather short dissolving time as currently programmed in the Sigma device seems 
to be a possible explanation for this problem . INTEM CT takes considerably longer compared 
to CT’s of the other assays, thereby providing more time for the process of liquefying. We 
conclude that CT values obtained by the Sigma device are unreliable. Future adaptation of 
the cartridge and elongation of the period of reagent dissolving are possible solutions for 
this issue.   
Comparison with other studies
To the best of our knowledge no previous studies have been conducted into the agreement 
between ROTEM® Delta and Sigma measurements in women experiencing postpartum 
haemorrhage. When looking at a non-pregnant population, we only found a trial 
registered by Tem Innovations GmbH (NCT02379104) into the method comparison of the 
ROTEM® Sigma with its predecessor model ROTEM® Delta to confirm equality of reference 
intervals; results are expected in December 2018. Some have studied agreement between 
ROTEM® FIBTEM parameters and Clauss fibrinogen concentrations. The peripartum use of 
thromboelastometry and  ROTEM® Delta were studied among 153 women and compared 
with fibrinogen concentrations assessed by the Clauss method11.  Samples drawn within 
one hour after childbirth showed only moderate correlation between ROTEM® FIBTEM 
parameters and fibrinogen concentrations: Spearman’s rank correlation coefficients were 
0.57 (A10), 0.56 (A20) and 0.56 (MCF).  Another study into the bedside assessment of 
fibrinogen concentration in postpartum haemorrhage by thromboelastometry reported on 
results of 37 women experiencing postpartum haemorrhage12. Correlation between Clauss 
fibrinogen concentration and ROTEM® FIBTEM parameters A 5, A15 and MCF was found to 
be strong (rs 0.84 to 0.86). The correlation between ROTEM
® FIBTEM and Clauss fibrinogen 
displayed in our cohort lies between values of correlation described in these earlier studies. 
In both articles, the authors did not state whether single or multiple-use reagent was used. 
Clinical implications
During acute situations like postpartum haemorrhage, clinicians are keen to get fast, 
yet reliable results on a patient’s fibrinogen status. Results from ROTEM® FIBTEM assays 
of the devices differed significantly, especially in the earlier measurements (A5 and A10) 
emphasizing the need to validate new devices before implementation and obtain device 
specific reference ranges, to inform appropriate device specific intervention points on 
an algorithm. Results of FIBTEM assays should be used with caution and should always 
be interpreted in the context of the specific device used, and all available patient and 
bleeding characteristics, because of the potential variation between measurements. 
Parallel sampling of Clauss fibrinogen level is advised to be used as a comparison in the 
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Conclusion
In our cohort of 23 women experiencing postpartum haemorrhage, we displayed a positive 
correlation between thromboelastometry assays EXTEM, INTEM and APTEM executed on 
the ROTEM® Delta and Sigma device: results of these assays from both devices are similar. 
CT values as obtained by the Sigma device are unreliable. A wide variation was shown 
between ROTEM® FIBTEM assays performed on both devices, especially in the earlier 
measurements (A5 and A10), important to acute clinical decision-making. Consequently, 
results of FIBTEM assays should be interpreted with caution and always in the context 
of device-specific reference values determining the intervention points on an algorithm. 
Correlation with Clauss fibrinogen was better in the ROTEM® Sigma device as compared 
to the Delta.
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S2.  Table  Correlation between FIBTEM and Clauss fibrinogen for Delta and   
 Sigma device
Delta Sigma
n rs p* n rs p*
CT s 21 -0.163 0.48 21 -0.011 0.96
A5 mm 21 0.695 <0.01 21 0.845 <0.01
A10 mm 21 0.681 <0.01 21 0.862 <0.01
A 20 mm 21 0.680 <0.01 21 0.841 <0.01
MCF mm 21 0.655 <0.01 21 0.821 <0.01
rs Spearman’s correlation coefficient, *correlation coefficients and p-value by Spearman’s rank test, CT Clotting 
Time, MCF Maximum Clot Firmness






ASSOCIATION BETWEEN CLAUSS FIBRINOGEN CONCENTRATION AND ROTEM® FIBTEM A5
Abstract
Background:  Point-of-care tests like FIBTEM A5 have been proposed to guide the 
treatment of patients who might have low fibrinogen concentrations (≤2 g/L). The aim 
of this study was to describe fibrinogen concentrations according to previously proposed 
FIBTEM A5 cut-off points in blood samples collected from women during persistent 
postpartum haemorrhage. 
Methods: Prospective multicentre cohort study in 511 women sustaining postpartum 
haemorrhage. A total of 637 blood samples were drawn during haemorrhage. Clauss 
fibrinogen concentrations and ROTEM® FIBTEM A5 values were studied to assess the 
diagnostic properties of previously proposed FIBTEM A5 cut-off points for the detection 
of low fibrinogen concentrations. 
Results: Of 511 women with a median total volume of blood loss of 1500 mL (IQR 1200 
to 2000) 31 women (6%) developed Clauss fibrinogen concentrations below 2 g/L. Using 
FIBTEM A 5 cut-off of ≤ 7 mm: 48% of cases with Clauss fibrinogen ≤2 g/L were missed 
(FIBTEM A5 > 7mm), and of the 28 samples with FIBTEM A5 ≤ 7mm, 12 (43%) samples 
had Clauss fibrinogen >2 g/L. Using FIBTEM A5 cut-off of ≤12mm: 13% of cases with 
Clauss fibrinogen ≤2 g/L were missed and of the 145 samples with a FIBTEM A5 ≤12 mm, 
118 had Clauss fibrinogen >2 g/L, resulting in false positive selection of 81% of women. 
Using FIBTEM A5 ≤ 15 mm: 97% (30/31) of the samples with Clauss fibrinogen ≤2 g/L were 
accurately selected; yet 89% (248/278) of samples that were selected had a fibrinogen 
concentration of >2 g/L. Based on the Youden index, the optimal cut-off point in our 
cohort was a FIBTEM A5 of 12mm with sensitivity 87% and specificity 81%.
Conclusions: Our findings suggest that if FIBTEM A5 lower than 12 mm would have 
been used to detect women with fibrinogen concentrations below 2 g/L in order to 
treat them with fibrinogen concentrate, 87 % of the women with fibrinogen below 2 
g/L would correctly have received fibrinogen. However, most women (81%) receiving 
fibrinogen concentrate would not have needed it, because they had plasma fibrinogen 
concentrations above 2 g/L.  
Introduction
Postpartum haemorrhage remains one of the leading maternal health problems 
worldwide1, 2. Although in most women the primary cause is obstetric, acquired 
haemostatic impairment may aggravate bleeding3, 4. From previous studies, a low 
fibrinogen concentration emerges as the earliest predictor of progression towards severe 
postpartum haemorrhage5, 6,7-10. By timely detection of low fibrinogen concentrations, 
targeted haemostatic therapy may be administered to restore adequate concentrations 
of fibrinogen. The Clauss fibrinogen assay is the standard coagulation test to assess 
fibrinogen concentration. Its downside is a turn-around time of up to 60 minutes, 
rendering this test unsuitable for clinical decision making in the acute setting11. Point-
of-care devices like ROTEM® thromboelastometry can detect changes in the coagulation 
system within ten minutes from blood sampling4. In trauma, cardiac and liver surgery, 
thromboelastometry is increasingly used to predict bleeding, diagnose fibrinogen 
deficiency and guide fibrinogen administration. Evidence is emerging that ROTEM-guided 
transfusion strategies may reduce the need for blood products and bleeding-associated 
morbidity12.  ROTEM® devices are becoming more widely available in maternity wards, 
where treatment is generally dependent on local algorithms. Several studies in women 
sustaining postpartum haemorrhage found that fibrinogen concentrations below 2 g/L 
were associated with progression towards more severe postpartum haemorrhage5-9, 13. 
The ROTEM® FIBTEM A5 assay, available within 7 to 10 minutes after sampling, may provide 
a quantitative assessment of the plasma concentration of fibrinogen of women during 
postpartum haemorrhage and has been established as an early biomarker for progression 
towards more severe postpartum haemorrhage4, 13, 14. However, the diagnostic properties 
of FIBTEM A5 to accurately identify Clauss fibrinogen concentrations ≤2 g/L remain unclear. 
In a previous trial comparing administration of fibrinogen concentrate with placebo in 
women with postpartum haemorrhage, a FIBTEM A5 cut-off of 15 mm was used and no 
difference was observed between groups with regard to number of units of red blood 
cells, plasma, cryoprecipitate and platelets transfused15. An earlier study in women with 
postpartum haemorrhage suggested a FIBTEM A5 value of 6 mm as the cut-off point that 
correlates best with Clauss fibrinogen below 2 g/L.   To create reliable ROTEM®- based 
treatment algorithms for use during postpartum haemorrhage, the properties of the 
FIBTEM A5 test to detect Clauss fibrinogen concentrations below 2 g/L among women at 
risk of severe outcome of postpartum haemorrhage needs to be established. 
The aim of this study was to describe fibrinogen concentrations according to previously 
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Methods
Design and study population
We studied women who had been included in the TeMpOH-2 (Towards better Prognostic 
and Diagnostic strategies for Major Obstetric Haemorrhage) study, a prospective cohort 
of pregnant women in the Netherlands between February 2015 and April 2018. Women 
were recruited during pregnancy at the outpatient clinics and maternity wards of three 
participating hospitals: the Leiden University Medical Center, the Erasmus Medical Centre 
Rotterdam and the Zwolle Isala Clinics. 
Included women were monitored for the occurrence of postpartum haemorrhage 
(≥1000 mL blood loss within 24 hours from childbirth) and followed until discharge from 
hospital. All subjects were treated according to the Dutch regulations for prevention and 
management of postpartum haemorrhage16. Blood samples were drawn from women in 
case they developed postpartum haemorrhage. Up to three samples per woman were 
sampled, with the first sample drawn at a blood loss between 1000-1500mL, but in some 
cases pragmatically drawn from 800mL of blood loss at time of achieving intravenous 
access. Subsequent samples were drawn in case of an additional volume of blood loss 
of 1000-1500mL. Both a ROTEM® FIBTEM assay and fibrinogen concentration assessed 
by the Clauss method were performed. A Clauss fibrinogen concentration of ≤2g/L was 
considered to be a low fibrinogen level.  FIBTEM cut-off points of 7, 12 and 15 mm that were 
used in previous studies as an equivalent of a low fibrinogen (≤2g/L) were compared to 
Clauss fibrinogen concentrations. ROTEM thromboelastometry results were not available 
to treating clinicians. During the inclusion period of the TeMpOH-2 study, the ROTEM® Delta 
was replaced by the ROTEM® Sigma device. On the ROTEM® Sigma device, measurements 
are performed in a fully automated manner. In one of the study sites measurements were 
performed simultaneously with both devices17. Approval for the study was obtained 
from the Ethical Committee of the Leiden University Medical Centre (P13.246) and from 
the institutional review board of each participating hospital. The study was registered 
at ClinicalTrials.gov (NCT02149472). The ethical committee provided the possibility to 
ask women for verbal informed consent during early postpartum haemorrhage in case 
they had not yet been included in the study during pregnancy. The present analysis was 
restricted to data from women who provided written informed consent for their data to 
be used in the study. Women below 18 years of age or with a gestational age below 24 
weeks at the time of birth were excluded. Women with coagulation disorders or who used 
anticoagulants were not excluded. 
Data collection
Information on maternal and obstetric characteristics was collected by well-trained 
research nurses who performed comprehensive chart reviews. Data were recorded from 
medical files available at the maternity ward for the following parameters: maternal age 
at the time of birth, parity, gestational age, mode of birth, presence of pre-eclampsia or 
HELLP syndrome, presence of a coagulation disorder, anticoagulant use and total volume 
of blood loss, primary cause of major obstetric haemorrhage, abnormal placentation, 
shock, volume and timing of administration of fluids and blood products, performance 
and timing of surgical and haemostatic interventions, and consecutive measurements 
of blood loss until cessation of bleeding. Blood loss was measured by weighing gauzes 
and all other soaked materials and by use of a collector bag and suction system in the 
operating theatre. 
Handling of ROTEM® devices and measurements 
In two of the participating hospitals, the ROTEM® devices were positioned at the laboratory 
and samples were handled by laboratory staff. In the other hospital, the devices were 
positioned in a utility room equipped to house laboratory devices at the maternity ward. 
Here, ROTEM® measurements were performed by well-trained study personnel including 
research nurses and well-trained clinical midwives. In case measurements could not be 
started immediately, citrated blood samples were stored and handled at 37ºC. Results were 
only taken into consideration when measurements had started within 4 hours after blood 
sampling, since sample stability up to 4-6 hours has been confirmed in previous studies18, 19. 
Blood draw was performed by venepuncture using a 21 -gauge blood collection needle or 
following insertion of a peripheral vein cannula. Blood was collected in vacuum tubes (BD 
Vacutainer® Citrate tubes 3.2% and BD Vacutainer® spray-coated K2EDTA tubes), always 
discarding the first 3 mL of blood. Citrated tubes were collected before EDTA tubes. Visual 
inspection was conducted to verify if the minimum acquired volume of blood had been 
collected. If not, the tube was discarded. In case samples were not handled directly at the 
maternity ward, tubes were sent to the laboratory by pneumatic tube system transport. 
Blood samples for Clauss fibrinogen assays were handled immediately after arriving at the 
laboratory and centrifuged for 10 minutes at 2700 g at a temperature of 20ºC.  External 
quality control for Clauss fibrinogen, APTT and PT and (in two of three participating 
hospitals)  ROTEM® parameters  was secured by participation in the international External 
Quality Assessment Programme (EQAP) by ECAT.  Internal quality control was performed 
weekly by using the quality control reagents ‘ROTROL N’ (normal control)  and ‘ROTROL 
P’ (abnormal control) provided by the manufacturer. Also, daily, quarterly and yearly 
maintenance on the devices was carried out according to the manufacturer’s instructions. 
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Statistical analyses
Characteristics of women are reported using descriptive statistics. Clauss fibrinogen and 
ROTEM® parameters are presented as median and interquartile ranges because of their 
non-Gaussian distribution. In case of multiple samples per woman these were all taken 
into account in the analysis. All ROTEM® parameters were verified by visually inspecting 
corresponding temograms for normal lay-out and by checking all parameters for error 
codes. Incorrect values were excluded from analysis. Spearman’s rank correlation 
coefficients (rs) were assessed for the correlation between ROTEM® FIBTEM values of both 
devices and fibrinogen concentration as obtained by Clauss assay20. Sensitivity, specificity, 
positive and negative predictive value and the area under the receiver operator curve 
(AUC’s) were calculated to assess the diagnostic properties of FIBTEM A5 to discriminate 
women with and without a fibrinogen concentration of ≤2g/L. The cut-off with the highest 
sensitivity and specificity  was determined by use of the Youden index, which defines the 
maximum potential effectiveness of a test21.   A complete case analysis was performed, 
data were not imputed. 
Results
Women characteristics 
Over the three-year inclusion period, 17203 women gave birth in the participating 
hospitals. Of all women, 1605 suffered postpartum haemorrhage defined as a volume 
of blood loss of ≥1000 mL  within 24 hours from childbirth and 591 women agreed to 
participate in the study. For 511 women, valid corresponding measurements of fibrinogen 
and FIBTEM A5 were available resulting in 637 samples (Figure 1). Baseline characteristics 
are reported in Table 1. Women were on average 32 years of age (interquartile range (IQR) 
28 to 35), gave birth at a median gestational age of 39.4 weeks (IQR 38.0 to 40.6) and 
in 23% by caesarean section. Median total volume of blood loss was 1500mL (IQR 1200 
to 2000) and the most prevalent causes of haemorrhage were atony and/or retained 
placenta in 76% of women. One sample was available for 397 women, a second sample 
for 102 and a third sample for 12 women. 
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Table 1.  Women characteristics
Women
Maternal characteristics n =511
        Age in years 32 (28 to 35)*
        BMI in kg/m2 24 (22 to 28) *
        Ethnicity, Caucasian 86%
        Gestational age in weeks 39.4 (38.0 to 40.4) *
        Nulliparity 51%
Risk factors PPH
        Pre-eclampsia/HELLP 4%
        Anti-coagulant use 3%
        Known coagulation   disorder
        Multiple pregnancy 9%
Mode of birth
        Vaginal 77%
        Caesarean section 23%
Primary cause of bleeding
        Uterine atony 35%
        Retained placenta or remnants of placental       tissue 41%
        Surgical bleeding 9%
        Genital tract trauma 9%
        Placenta praevia 2%
        Pathological ingrowth of placenta 1%
        Placental abruption 2%
        Uterine rupture 1%
        Coagulopathy 0%
Bleeding
        Total volume of clear fluids (L) 1.0 (0.5 to 2.0) *
        Total units of blood products (n) 0 (0 to 0) *
        Total volume of blood loss (n) 1500 (1200 to 2000) *
Samples
Sample 1000-1500mL n=412
    Blood loss at sampling time (L) 1.0 (0.9 to 1.2) *
    Units of RBC received at sampling time (n) 0.0 (0.0 to 0.0) *
    Fluids received at sampling time (L) 1.0 (0.0 to 2.0) *
Women
Sample 1500-2500mL n=185
    Blood loss at sampling time (L) 1.8 (1.5 to 2.0) *
    Units of RBC received at sampling time (n) 0.0 (0.0 to 0.0) *
    Fluids received at sampling time (L) 2.0 (1.0 to 4.0) *
Sample >2500mL n=40
        Blood loss at sampling time (L) 2.7 (2.5 to 3.4) *
        Units of RBC received at sampling time (n) 0.0 (0.0 to 2.0) *
        Fluids received at sampling time (L) 3.0 (2.0 to 6.0) *
Total n=637
    Blood loss at sampling time (L) 1.2 (1.0 to 1.6) *
    RBC received at sampling time 0.0 (0.0 to 0.0) *
    Fluids received at sampling time (L) 1.0 (1.0 to 3.0) *
* All values in the table reported in this format are median and (IQR)
 
Clauss Fibrinogen and FIBTEM A5 levels observed in cohort
In total 637 valid combinations of measurements of Clauss fibrinogen and FIBTEM levels 
were obtained. Median FIBTEM A5 level was 17mm (IQR 13 to 20) and median Clauss 
fibrinogen concentration 3.9 g/L (IQR 3.1 to 4.5). Of the 511 women, 31 (6%) had a Clauss 
fibrinogen concentration of ≤2 g/L. 
Correlation Clauss fibrinogen ROTEM® FIBTEM A5
In the 637 samples, overall correlation between Clauss fibrinogen concentration and 
FIBTEM A5 showed a Spearman’s correlation coefficient (rs) of 0.64 (95% Confidence 
Interval (CI): 0.60 to 0.69). Spearman’s correlation coefficient between Claus fibrinogen 
concentration and FIBTEM measured on the ROTEM® Delta and Sigma device were (rs) 0.63 
(95% CI: 0.58 to 0.67) and (rs) 0.76 (95% CI: 0.63 to 0.85) respectively (Figure 2). Within the 
three sample categories, Spearman’s correlation coefficients improved with increasing 
volumes of blood loss (Table 2).
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Figure 2. Scatterplot correlation Clauss fibrinogen and FIBTEM A 5
Table 2.  Fibrinogen concentration as assessed with the Clauss assay,   
  ROTEM® FIBTEM A5 values and their correlations according   
  to increasing volumes of blood loss among 511 women    
  with postpartum haemorrhage.







correlation  (rs) 
(95% CI) †
1.0-1.5 L (n = 412) 1.0  (0.9 to 1.2) 4.1 (3.5 to 4.7) 18 (14 to 20) 0.56 (0.48 to 0.62)
1.5-2.5 L  (n = 185) 1.8  (1.5 to 2.0) 3.5 (2.9 to 4.1) 15 (12 to 18) 0.67 (0.58 to 0.74)
> 2.5 L (n = 40) 2.7  (2.5 to 3.4) 2.7 (2.2 to 3.3) 12 (10 to 16) 0.79 (0.64 to 0.89)
All samples (n = 637) 1.2 (1.0 to 1.6) 3.9 (3.1 to 4.5) 17 (13 to 20) 0.64 (0.60 to 0.69)
* Values in the table reported in this format are median and (IQR), † Spearman’s correlation (rs) (95% CI)
 
Discriminative ability of FIBTEM A5 for low fibrinogen concentration and cut-off 
points
The ability of FIBTEM A5 to select observations with a Clauss fibrinogen concentration 
of ≤2 g/L was good, area under Receiver Operating Curve 0.92 (95% confidence interval 
(CI) 0.87 to 0.97). Based on the Youden index, the best cut-off point in our cohort was 
12mm with a sensitivity of 87% and specificity of 81%, missing 4 of the 31 cases (13%) of 
a Clauss fibrinogen ≤2 g/L and false positively selecting 118 cases (81%) (Table 3). When 
15 mm was used as FIBTEM A5 cut-off point, 97% (30/31) of the samples with a Clauss 
fibrinogen ≤2 g/L were accurately selected, but 89% (248/278) of selected samples had a 
fibrinogen concentration >2 g/L. When a lower cut-off value for FIBTEM A5 was chosen, 
these numbers changed: a cut-off value of FIBTEM A5 of 6 mm accurately selected 26% 
(8/31) of samples with a Clauss fibrinogen concentration of ≤2 g/L and 74% (23/31) of 
samples with a low fibrinogen were missed. Yet, a lower percentage of 53% (9/17) of 
samples that were selected based on FIBTEM A5 value < 7 mm had corresponding Clauss 















































































































































































































































































































































































































































































































































































Based on the Youden index, the optimal cut-off point in our cohort was a FIBTEM A5 
of 12mm. If FIBTEM A5 would have been used to detect women with a low fibrinogen 
concentration in a treatment algorithm that uses the 12 mm cut-off to initiate 
administration of fibrinogen concentrate, 87 percent of women in need of fibrinogen 
would have been treated.  However, a large majority of women (81%) would have received 
fibrinogen concentrate despite normal plasma fibrinogen concentrations.  
Strengths and limitations
To the best of our knowledge this is the largest study to date to describe fibrinogen 
concentrations according to previously proposed FIBTEM A5 cut-off points in blood 
samples collected from women suffering postpartum haemorrhage. The strength of this 
prospective study is that we were able to include a large cohort of women sustaining 
postpartum haemorrhage with repeated blood samples containing set panels at 
established times during postpartum haemorrhage. This enables for reliable and 
generalizable estimation of correlation and determination of interventional cut-off points 
based on Clauss fibrinogen and FIBTEM A5 levels. The prospective design of our study 
also has limitations: although the majority of women consented to participate in the 
study during their pregnancy, or in case they did not give consent yet, the opportunity 
was created to provide verbal consent during early postpartum haemorrhage, we 
did experience the challenge of performing study procedures in acutely ill women as 
described by others15. A total of 31 (6.1%) of the 511 women in our cohort developed 
a Clauss fibrinogen concentration ≤2g/L. Keeping track of missed cases that could have 
been included in the study, we noticed that women who lost a large volume of blood in a 
short period of time were more frequently not included in the study due to lack of time and 
personnel to perform study procedures in such an acute situation. This may have led to an 
underestimation of the incidence of a Clauss fibrinogen concentration ≤2g/L. However, 
the incidence of a Clauss fibrinogen concentration ≤2g/L in our source population of 
women giving birth during in the participating hospitals during the inclusion period was 
0.2% (31/17203) which is exactly the same (0.2%, 342/191772) as observed in a previous 
study with the same source population (women giving birth in the Netherlands)10. 
Comparison with other studies
Correlation between Clauss fibrinogen concentration and FIBTEM A5 in women 
experiencing postpartum haemorrhage has been described in two previous studies. 
One observational study with postpartum haemorrhage (>500mL after vaginal birth 
or >1000mL after caesarean section) found a Spearman’s correlation coefficient (rs) of 
0.86 for the haemorrhage group and rs 0.83 for the control group
22.  No information was 
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samples with a Clauss fibrinogen ≤2g/L, yet correlation coefficients were similar for both 
groups, whereas we found an increase in correlation with higher volumes of blood loss. 
Another study into FIBTEM A5 as a biomarker for progression of postpartum haemorrhage 
found a moderate correlation in 312 paired Clauss fibrinogen and FIBTEM A5 assays of 
rs 0.59
13. These assays were sampled at study entry, at a median volume of blood loss of 
1200mL. Our findings corroborate these results with a rs of 0.55 at 1000mL and rs of 0.67 
at 1800mL. The choice for a cut-off point for a diagnostic test depends on the risks for 
adverse outcomes when patients are incorrectly classified and/or incorrectly treated. 
Since the risk of adverse outcomes is very high when fibrinogen concentrations are below 
2 g/L, sensitivity of the test to diagnose all women with fibrinogen below 2 g/L should be 
high. At the time of writing, there is no consensus on an optimal cut-off point for FIBTEM 
A5 and results of previous studies lack conformity in their conclusions. In the previously 
cited study with high correlation between FIBTEM A5 and Clauss fibrinogen, a FIBTEM 
A5 level of 6 mm was found to correspond best (sensitivity 100%, specificity 87%) to the 
threshold of Clauss fibrinogen ≤2g/L22. Yet, in other studies, a FIBTEM A5 level of 12mm 
and 15 mm were considered the equivalent of a Clauss fibrinogen concentration of 2 and 
3 g/L respectively13, 15, 23. No additional explanation was provided to support the choice 
for these thresholds. In a double-blind randomised controlled trial (OBS2), the effect of 
early fibrinogen replacement in women during postpartum haemorrhage guided by 
thromboelastometry was examined15. In this study women, with a FIBTEM A5 value of 
≤15mm were randomised to treatment with fibrinogen concentrate or placebo based on 
an earlier observational study of the same research group, which found that a FIBTEM 
A5 value of ≤ 15mm was associated with progression of postpartum haemorrhage. No 
reduction of allogeneic blood product transfusion or volume of blood loss was observed. 
Also, a subgroup analysis in women with a FIBTEM A5 value of ≤ 12mm showed no 
significant differences between groups. However, in this study only seven women 
developed a Clauss fibrinogen concentration ≤2 g/L.  
Clinical implications
During acute situations like postpartum haemorrhage, clinicians are keen to get fast, 
reliable results on a woman’s coagulation status. FIBTEM A5 has been promoted to diagnose 
fibrinogen deficiency and guide treatment with fibrinogen concentrate. Assuming that 
women suffering postpartum haemorrhage with a Clauss fibrinogen concentration of 
≤2 g/L require administration of fibrinogen concentrate, FIBTEM A5 is useful but lacks 
specificity. Using FIBTEM A5 with a cut-off point of 12 mm will lead to large numbers of 
women receiving fibrinogen concentrate in vain. The development of a point-of-care test 




Based on the Youden index, the best cut-off point to accurately select women with a 
Clauss fibrinogen concentration of ≤2 g/L is FIBTEM A5  of 12mm. Yet, treatment of all 
women with FIBTEM A5 lower or equal than 12 mm with fibrinogen concentrate will 
lead to inappropriate use of fibrinogen in about 80 percent of women with postpartum 
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TRANEXAMIC ACID DURING PERSISTENT POSTPARTUM HAEMORRHAGE
Abstract
Background: Recent results show a protective effect of tranexamic acid on death due 
to bleeding in patients with postpartum haemorrhage in low- and middle-resource 
countries. We quantify the association between early administration of tranexamic acid 
compared to late or no administration and severe acute maternal morbidity and blood 
loss among women suffering from persistent severe postpartum haemorrhage in a high-
income country.
Methods and findings: We performed a nationwide retrospective cohort study in 61 
hospitals in the Netherlands. The study population consisted of 1260 women with 
persistent postpartum haemorrhage who had received at least four units of red cells, 
or fresh frozen plasma or platelets in addition to red cells. A review of medical records 
was performed and cross-referenced with blood bank data. The composite endpoint 
comprised maternal morbidity (hysterectomy, ligation of the uterine arteries, emergency 
B-Lynch suture, arterial embolization or admission into an intensive care unit) and mortality.
Results: 247 women received early tranexamic acid treatment. After adjustment for 
confounding, odds ratio for the composite endpoint for early tranexamic acid (n = 247) 
versus no/late tranexamic acid (n = 984) was 0.92 (95% confidence interval (CI) 0.66 to 
1.27). Propensity matched analysis confirmed the absence of a difference between women 
with and without tranexamic acid. Blood loss after administration of first line therapy did 
not differ significantly between the two groups (adjusted difference -177 mL, CI -509.4 to 
+155.0).
Conclusions: Our findings suggest that in a high-resource country the effect of tranexamic 
acid on both blood loss and the combined endpoint of maternal mortality and morbidity 
may be disappointing.
Introduction
Major obstetric haemorrhage during pregnancy, delivery and puerperium continues to be 
an important health problem around the world. In low-resource countries, it remains the 
leading cause of maternal mortality. In high-resource countries it accounts for almost half of 
all severe acute maternal morbidity1-4
As part of management of major blood loss, haemostatic agents may be administered to 
support coagulation and correct for acquired coagulopathy5,6. One of these is tranexamic 
acid, an antifibrinolytic agent inhibiting dissolution of the fibrin clot by binding to 
plasminogen and blocking the interaction of plasmin(ogen) with fibrin7. Tranexamic acid 
has been shown to reduce blood loss and the need for blood transfusion in both elective 
and emergency surgery8. Blood loss after caesarean and vaginal births was also found 
to be somewhat reduced by administration of tranexamic acid in absence of significant 
maternal and neonatal complications9. In severely bleeding trauma patients, tranexamic 
acid was found to reduce mortality by 10–15%10. Moreover, the CRASH-2 trial and the 
WOMAN trial have shown that treatment with tranexamic acid should be started as early 
as possible to result in the largest effect11,12.
In theory, postpartum haemorrhage provides an additional indication for tranexamic 
acid because rapid degradation of fibrinogen and fibrin and increased activation of 
plasminogen activators occur at placental expulsion7,13. Tranexamic acid has a half-life of 
three hours and adequate therapeutic levels persist for 7–8 hours following intravenous 
injection.
Tranexamic acid is inexpensive, available in many settings, and has a good safety profile. 
Given the hypercoagulable status of pregnant women, possible thromboembolic side 
effects of tranexamic acid administration have been the subject of earlies studies. 
Reported adverse events were mainly minor and no clear evidence was found for an increase 
of thromboembolic events in pregnant women who were administered with a low dose of 
tranexamic acid9.
Recently, the results of the WOMAN trial that compared tranexamic acid in an early stage 
of postpartum haemorrhage to placebo, showed a reduction of maternal mortality due to 
bleeding from 1.9% to 1.5%. However, this trial was conducted primarily in low-resource 
settings and no differences were found in all-cause mortality or other clinical endpoints 
concerning maternal morbidity. Also, the effect of tranexamic acid on the amount of blood 
loss was not studied. Since maternal mortality has become a rare event in high-resource 
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the course of postpartum haemorrhage has a positive effect on clinical outcome or amount 
of blood loss in a high- resource setting.
The aim of this study was to quantify the association between tranexamic acid administration 
at an early stage in the course of persistent postpartum haemorrhage and severe acute 
maternal morbidity and blood loss in a high-resource setting.
Methods
Design and study population
We performed a retrospective cohort study among women who experienced 
postpartum haemorrhage as part of the Transfusion strategies in women during Major Obstetric 
Haemorrhage study (TeMpOH-1). TeMpOH-1 is a nationwide retrospective cohort study 
in 61 hospitals in the Netherlands (75% of all hospitals in the country). The TeMpOH-1 
study was approved by the Ethical Committee of the Leiden University Medical Center 
(P12.273) and by the institutional review board of each participating hospital. Because 
of the retrospective design of the study, the need to obtain informed consent was waived 
by the ethics committee. Data were collected retrospectively from medical files of women 
≥18 years old, who had received four units of red blood cells or any transfusion of fresh 
frozen plasma (FFP) and/or platelets in addition to red blood cells because of obstetric 
haemorrhage between January 1st, 2011 and January 1st, 2013. Women were identified 
by cross-referencing electronic data from the hospitals’ blood transfusion services with 
local birth registers in participating hospitals. Data were recorded from medical files 
available at the delivery ward, operating theatre and intensive care unit for the following 
parameters: maternal age at the time of delivery, parity, maternal body weight during 
early pregnancy, maternal height, ethnicity, gestational age, obstetric history, mode of 
delivery, cause of major obstetric haemorrhage, abnormal placentation, shock, timing and 
volume of fluids and blood products transfused, medical and surgical interventions and 
repeated measurements of blood loss until cessation of bleeding. Blood loss was measured 
by weighing gauzes and all other soaked materials and by the use of a collector bag and 
suction system in the operating theatre. Information on possible side effects of treatment 
with tranexamic acid was not available due to the design of the study.
Selection of women with persistent postpartum haemorrhage
In order to avoid use of case definitions based on mere estimations of blood loss and 
in absence of a universal definition of severe postpartum haemorrhage, we opted for a 
practically derived definition. First, we selected those women from our cohort, who had 
primary postpartum haemorrhage within 24 hours after birth. To meet the criteria of severe 
postpartum haemorrhage, bleeding had to persist despite the timely administration of first 
line therapy14.
Women were treated according to the Dutch national guideline on postpartum 
haemorrhage, which advises to initiate first line therapy without delay in case of persisting 
haemorrhage despite administration of prophylactic uterotonic agents. First line therapy 
was defined as per primary cause of bleeding (Table 1). By applying this pragmatic definition 
to our cohort, only cases of ongoing haemorrhage (despite administration of first line 
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Table 1.  First line therapy as per primary cause of bleeding. 
Primary cause of bleeding Corresponding first line therapy
Uterine atony Administration of uterotonic agents* and/ or 
inspection of the uterine cavity
Retained placenta Manual removal of placenta
Traumatic cause (uterine rupture, trauma of the 
birth canal)
Surgical repair
Surgical cause Surgical repair
Placental abruption and placenta praevia Caesarean section †
* The uterotonic agents administered were Oxytocin or Misoprostol.
† In case of stillbirth no caesarean section was performed
 
Early versus late/no tranexamic acid
In our study, the effect of tranexamic acid was compared between patients who had received 
tranexamic acid early during persistent postpartum haemorrhage and patients who had not 
received tranexamic acid or who had received tranexamic acid at a later stage. Women who 
received tranexamic acid late were grouped with women who did not receive tranexamic acid 
at all. This allocation was chosen because at the early decision moment whether to administer 
tranexamic acid or not, the choice in these both groups was to refrain from administration of 
tranexamic acid. Thus, a control group was created of women who did not receive tranexamic 
acid at the early decision moment. The administration of tranexamic acid within one hour 
after the start of first line therapy was considered “early” administration. This cut-off point 
was based on the results of the CRASH-2 trial, which showed a positive effect on mortality 
in women who received tranexamic acid within an hour and between one and three hours 
after trauma. In patients who received tranexamic acid after three hours this positive effect 
disappeared12,15. Because administration of tranexamic acid in the late treatment group 
of the TeMpOH-2 cohort exceeded this three hours’ time limit, these women were analysed 
together with the women that did not receive tranexamic acid at all.
Outcome definitions
The primary outcome was a combined endpoint of maternal mortality and severe 
acute maternal morbidity. Emergency peripartum hysterectomy, ligation of the uterine 
arteries, B-Lynch suture (in the Netherlands only used as emergency procedure), arterial 
embolization or admission into an intensive care unit were considered endpoints of maternal 
morbidity. Secondary outcomes were total blood loss (blood loss at the end of postpartum 
haemorrhage), additional blood loss (additional blood loss between administration of 
first line therapy and the end of postpartum haemorrhage), volume and number of blood 
products transfused.
Confounding and effect modifiers
The following parameters were pre-defined as possible confounders for the association 
between administration of tranexamic acid and outcomes: maternal age, body mass index 
(BMI), mode of delivery, primary cause of major obstetric haemorrhage and abnormal 
placentation. Also, the following bleeding characteristics at first line therapy were regarded 
as potential confounder: amount of blood loss, bleeding rate, shock, administration of 
other haemostatic agents, amount of fluids and amount of blood products that had been 
administered at first line therapy.
Haemorrhagic shock was defined as systolic blood pressure of 90 mmHg or less, or a heart 
rate of 120 bpm or higher16. Bleeding rate was calculated as the amount of blood loss in 
millilitres per minute. In the cohort, active management of labour (standard administration 
of oxytocin, controlled cord traction and uterine massage for prevention of postpartum 
haemorrhage) was practiced according to the Dutch national guidelines.
Statistical analyses
Characteristics and outcomes are reported using descriptive statistics. In order to prevent 
bias due to missing data in covariates, we used multiple imputation. The associations 
between early versus no/late tranexamic acid administration and outcomes were 
assessed using logistic and linear regression models. The multivariate models were 
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Results
Patient characteristics
The TeMpOH-1 cohort comprised 1391 women who had received at least four units of 
red cells (66%), or fresh frozen plasma or platelets in addition to red cells, for postpartum 
haemorrhage. For the present analysis, we selected all 1260 women who fulfilled the 
definition of persistent post- partum haemorrhage. Patient selection is presented in Figure 1. 
Uterine atony was the primary cause of bleeding in 789 (62%) and retained placenta in 215 
(17%) women. The median total blood loss was 3000 mL (IQR 2500–4000 mL). Primary causes 
of bleeding and other patient characteristics are presented in Table 2. Median amount of 
blood loss after administration of first line therapy in the selected cohort with persistent 
bleeding was 2125 ml (IQR 1200–3021 ml).
Early versus late/no tranexamic acid administration
Of 1260 women with persistent postpartum haemorrhage 540 (42.8%) were treated with 
tranexamic acid, of whom 247 at an early stage, i.e. within one hour after the start of first 
line therapy. Among women who had received tranexamic acid early, 73% had received it 
at a single occasion and 21% had received tranexamic acid twice. The mean dosage per 
tranexamic acid gift was 1.1 grams (range 0.1 to 3.0 grams) and administration occurred 
intravenously. In the early treatment group, administration of tranexamic acid occurred 1.6 
hours after birth (95%CI 1.3–1.9), compared to 4.6 hours (95%CI 4.1–5.1) in the late treatment 
group. Because of the presumed absence of benefits of administration of tranexamic 
acid beyond the 3-hour time interval as described in the Crash-2 trial, women in the late 
treatment group were analysed together with women who did not receive tranexamic acid 
at all.
Table 2 presents patient characteristics according to early versus late/no tranexamic acid 
administration. Given the relatively large proportion of women in the Dutch maternity 
care system delivering with a midwife outside a hospital setting, data on location of 
delivery and transfer to a hospital were studied between groups. No statistically significant 
differences were found. Delivery by caesarean section and bleeding due to atony had 
occurred more frequently among women with early tranexamic acid administration, 
compared to women with late/no tranexamic acid administration (29% vs 21%, and 68% 
vs 63% respectively). In addition, women who had received tranexamic acid early, bled 
more severely at onset of first line therapy: bleeding rate (24 vs 19 ml/min), blood loss at 
diagnosis of first line therapy (1300 ml vs 800 ml) and incidence of haemorrhagic shock 
(31% vs 21%) were all higher compared to late/ no tranexamic acid administration.
Figure 1.  Inclusion flowchart. 
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Table 2.  Patient characteristics and treatment characteristics at first line   
  therapy according to whether women had received tranexamic acid  
  early (within one hour after the start of first line therapy) or not early  






 Age, years* 33 (29–36) 31 (28–35)
 BMI (kg/m2)* 23 (21–26) 23 (21–27)
 Ethnicity†
  Caucasian 181 (73) 698 (71)
  Non-Caucasian 53 (21) 219 (22)
  Unknown 13 (5) 67 (7)
Obstetric Characteristics
 Nulliparity† (yes) 133 (54) 511 (52)
 Gestational age (weeks)* 40 (38–41) 40 (38–41)
Labour characteristics
 Mode of delivery†
  Vaginal 175 (71) 769 (78)
  Caesarean section 71 (29) 208 (21)
 Transfer to hospital
  No transfer (birth with midwife) 





 Primary cause of bleeding†
  Uterine atony 168 (68) 621 (63)
  Retained placenta 39 (16) 176 (18)
  Other 40 (16) 187 (19)
 Placentation†
  Abnormal localisation placenta 34 (14) 124 (13)
  Pathological ingrowth placenta 22 (9) 94 (10)
Treatment characteristics at first line therapy
 Fibrinogen-previously† 4 (2) 3 (0)
 Recombinant FVIIa-previously† 0 (0) 0 (0)
 Estimated blood loss previously, ml* 1300 (450–1933) 800 (150–1400)
 Bleeding rate, ml/min* 24 (14–43) 19 (9.2–38)
 Shock any time before first line therapy † 76 (31) 203 (21)
* median and (IQR)
†  number and %
Morbidity and mortality according to tranexamic acid administration
Six women died due to major postpartum haemorrhage (0.5%), of whom two had received 
early tranexamic acid. There was no clear consistent difference between women who had 
and those who had not received tranexamic acid early (Table 3). Adjusted odds ratio for the 
composite endpoint of maternal morbidity and mortality was 0.92 (95% confidence interval 
(CI) 0.66–1.27). There were no differences between early and late/no tranexamic acid in 
subsets of women with uterine atony, shock before first line therapy, blood loss above 2 
litres, or by mode of delivery. (Table 4)
Table 3.  Numbers and odds ratios (OR) of severe maternal morbidity,  
  maternal mortality, blood loss and transfusions after first line  






Crude OR  
(95% CI) or  
crude difference
Adjusted OR  
(95% CI)  
or difference*
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*ORs and differences were adjusted for pre-defined confounders: bleeding rate, measured blood loss, fluids and 
blood products administered at first line therapy; Occurrence of shock before first line therapy, primary cause of 
major obstetric haemorrhage abnormal placentation, maternal age, mode of delivery, previous administration of 
fibrinogen and rec FVIIa. Multiple imputation was used. 
† Patients that reached at least one of the predefined clinical endpoints (maternal mortality, hysterectomy/B-lynch/
arterial ligation, embolization, ICU admission. 
‡ Blood loss in ml, median & IQR are reported 
§ Difference between groups calculated by linear regression analysis 
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Blood loss after first line therapy
The volume of additional blood loss after first line therapy was 2150 mL among women who 
had received tranexamic acid early whereas among women who had not received tranexamic 
acid early the additional blood loss was 2100 mL, amounting to a total blood loss of 3300 
mL (+65% increase) vs 3000mL (+70% increase) in women who received early vs no/late 
tranexamic acid respectively. After adjustment for confounding the blood loss after first 
line therapy was slightly, but not statistically significant, lower among the women who had 
received early tranexamic acid (adjusted difference -177 mL, CI -509 to +155). Women 
who had received early tranexamic acid had been transfused 6 (IQR 4 to 10) units of blood 
products, which was similar to women who had not received tranexamic acid early (6 units, 
IQR 4 to 8).
Table 4.  Association between early administration of tranexamic acid versus  
  late/no tranexamic acid and outcomes among women with atony,   
  shock before first line therapy, volume of postpartum haemorrhage  
  more than 2 litres, after caesarean section, or vaginal delivery.  




Atony (n = 789) 0,95 (0,65–1,41) -270 (-649–110)
Shock present before first line therapy (n 
= 279)
0,96 (0,52–1,79) -105 (-662–452)
Postpartum haemorrhage > 2 litres (n = 
1121)
1,71 (0,79–3,68) -243 (-871–384)
Caesarean section (n = 279) 0,81 (0,44–1,46) -381 (-1407–645)
Vaginal delivery (n = 944) 1,02 (0,69–1,50) +26 (-277–329)
 
Sensitivity analyses
As a sensitivity analysis, we calculated propensity scores for receiving tranexamic acid early 
according to bleeding rate, measured blood loss, fluids and blood products administered 
at first line therapy, occurrence of shock before first line therapy, primary cause of major 
postpartum haemorrhage, abnormal placentation, maternal age, mode of delivery and 
previous administration of fibrinogen and recombinant FVIIa. Using nearest neighbour 
propensity score matching we could match 201 women who had received tranexamic acid 
early with women who had not received tranexamic acid early. Results of these analyses were 
similar to those of the main analysis. Results are provided in Table 5.
Table 5.  Outcomes according to TXA early or late/no among women selected  








Maternal mortality* - - -
Hysterectomy 13 (6,5) 8 (4,0) 1,71 (0,69–4,24)
Embolization 22 (10,9) 25 (12,4) 0,87 (0,47–1,60)
ICU admission 58 (28,9) 56 (27,9) 1,06 (0,68–1,64)
Composite morbidity/Mortality 72 (35,8) 66 (32,8) 1,16 (0,76–1,77)
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Discussion
In this nationwide study in a high-resource country, tranexamic acid administration at an 
early stage during the course of persistent postpartum haemorrhage was associated neither 
with lower maternal morbidity nor with reduced blood loss. Despite the large number of 
women in our cohort the confidence intervals were wide and the findings may indicate a 
protective as well as absence of any effect of tranexamic acid. Subgroup analyses did not 
reveal any particular group of women with persistent postpartum haemorrhage that might 
benefit from early tranexamic acid administration.
To the best of our knowledge this is the largest study to date into the effect of early 
treatment with tranexamic acid in patients with persistent postpartum haemorrhage in a 
high- resource setting. Our large sample size enables us to provide information on clinical 
endpoints in addition to volume of blood loss. In our study, women were included when 
in need of transfusion of at least 4 red blood cells or additional blood products because of 
persistent postpartum haemorrhage. Therefore, our results are generalizable to and may 
be included in meta-analyses examining women with severe postpartum haemorrhage. 
Some limitations to our study need to be discussed. Inherent to our observational design is 
bias due to confounding by indication. Such confounding bias will lead to underestimation 
of a possible protective effect of tranexamic acid. Despite the fact that timing of first line 
therapy will be similar between cases, severe cases of postpartum haemorrhage are more 
likely to receive early tranexamic acid as compared to less severe cases of postpartum 
haemorrhage. To minimize this bias, we measured and adjusted for all known and 
measurable confounders. In addition, we evaluated the robustness of our findings by 
matching women receiving early tranexamic acid with women with the same propensity 
scores. Nevertheless, we cannot exclude bias due to residual confounding and therefore 
our findings may be an underestimate of a possible truly protective effect of tranexamic 
acid in some women with postpartum haemorrhage. Previous studies focused on the use 
of tranexamic acid for prevention of postpartum haemorrhage, rather than treatment of 
postpartum haemorrhage6. Our results corroborate the findings of these studies. A recent 
systematic review and meta-analysis of RCTs that studied the effect of the prophylactic use 
of tranexamic acid for postpartum haemorrhage, showed a similar reduction in mean 
blood loss of 149 ml17. So far, few studies have looked at the effect of tranexamic acid on 
maternal outcome in the treatment of postpartum haemorrhage. The most important one 
is the recently published WOMAN trial, in which 20 060 women from mostly low-resource 
settings with blood loss above 500 ml were included. A reduction in maternal death due to 
bleeding from 1.9% to 1.5% was found. The largest effect occurred in the group of patients 
that received tranexamic acid within 1–3 hours after birth. Surprisingly no difference was 
found on (severe) maternal morbidity. The amount of brace sutures/ligation/embolization 
and blood products transfused was equal in the treatment and placebo group. And, the 
number of hysterectomies was higher in the tranexamic acid group. The different study 
settings and populations make it difficult to come to a fair comparison of the results of 
the studies. As also mentioned by the authors of the WOMAN trial, hysterectomy to stop 
postpartum haemorrhage often is a first  line treatment option in low resource setting, 
where in a high resource setting this treatment counts as a last resort. In the WOMAN trial 
treatment with tranexamic acid occurred at a lower level of blood loss, which is in line with 
the setting of the study and the relative lack of treatment and transfusion options. Despite 
these differences, in both settings no significant treatment effect was found of tranexamic 
acid on the outcome (severe) maternal morbidity. Since maternal mortality is rare in a high 
resource setting, the treatment effect on mortality as found in the WOMAN trial is expected 
to be negligible when translated to our study population, which is in line with our results on 
mortality. The effect of treatment with tranexamic acid on total amount of blood loss was not 
studied in the WOMAN trial18.
A French randomized controlled open-label trial studied the effect of high dose tranexamic 
acid (4 grams in 1 hour) versus placebo in 144 women with postpartum haemorrhage of 
more than 800 ml. Blood loss six hours after enrolment was lower in the tranexamic acid 
group, but the difference was only 48 ml, which seems clinically irrelevant19. A pre- and post-
implementation study from the same country compared high dose tranexamic acid (4 
grams in 1 hour) in 159 women with postpartum haemorrhage of more than 800 ml after 
vaginal birth and showed no difference in amount of blood loss, duration of bleeding or 
need for transfusion20. Both studies were rather small, and contained women with less 
severe post- partum haemorrhage compared to our cohort, making it difficult to assess 
major clinical outcomes. After the first trial some concern arose with regard to a possible 
association between high dosages of tranexamic acid and unexplained renal failure20. 
Treatment of postpartum haemorrhage with these high dosages of tranexamic acid was 
therefore discontinued in several French hospitals. Given the relatively low mean dose of 
tranexamic acid administered in our cohort, the chance of developing negative side effects 
due to tranexamic acid was considered to be low. The infusion strategy of tranexamic acid 
that was used in our cohort is similar to the protocol used in the Crash-2 and WOMAN trials. 
In the previous RCTs that evaluated the use of tranexamic acid in treatment of postpartum 
haemorrhage, a much higher dose (4 gram tranexamic acid in 1 hour, followed by infusion of 
1 gram per hour over 6 hours) was used, based on available data on reducing haemorrhage 
in cardiac surgery19. Taking into account the pro-coagulant status of pregnancy, limiting the 
dosage of tranexamic acid appears to be a safer choice.
The results of our study appear plausible given the underlying mechanisms and causes 
of postpartum haemorrhage21. Administration of tranexamic acid may partially block 
degradation of the fibrin clot, resulting in a decrease in the amount of blood loss. However, 
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origin21. Treatment of postpartum haemorrhage should, therefore, focus on solving the 
underlying obstetric cause first.
This study suggests no difference or a small reduction in blood loss after administration of 
first line therapy in women who are treated with tranexamic acid early during persistent 
postpartum haemorrhage. Early treatment with tranexamic acid during persistent 
postpartum haemorrhage does not demonstrate a significant favourable effect on the 
frequency of composite maternal morbidity and mortality. Judging from the promising 
results of early tranexamic acid treatment in trauma medicine and elective and acute 
surgery and the results of the WOMAN trial, its good safety profile (when administered in 
dosages of 15mg/kg) and the fact that tranexamic acid is inexpensive, there seem to be few 
reasons not to administer tranexamic acid early during the course of persistent postpartum 
haemorrhage, yet the effect on clinical endpoints may be limited or absent8,10.
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GENERAL DISCUSSION AND SUMMARY
General Discussion and Summary
While looking at the magnitude of health problems occurring in women experiencing 
postpartum haemorrhage worldwide, the overall goal of this thesis was to contribute 
to a reduction of the incidence of subsequent adverse maternal outcomes. In pursuit of 
this aim, research questions were posed corresponding to all three phases leading up to 
adverse outcome due to postpartum haemorrhage: (1) pregnancy (prior to childbirth), 
(2) early postpartum haemorrhage and (3) persistent postpartum haemorrhage.
Ad 1. Prediction prior to childbirth: are we able to predict -during the pregnancy- who 
is going to bleed excessively following childbirth? 
Ad 2. Prediction and diagnosis during early postpartum haemorrhage: can we identify 
women who will end up with adverse outcome during early postpartum haemorrhage and 
moreover, how will we be able to diagnose these women in a reliable and fast manner? 
Ad 3. Treatment options during persistent postpartum haemorrhage: when persistent 
bleeding has developed, do we have adequate haemostatic therapy to stop bleeding?
The findings of this thesis can be summarized as follows:
- The predictive value of a bleeding score for postpartum haemorrhage was found 
to be poor (chapter 2).  
- Detection of low levels of fibrinogen and elevated aPTT levels during early 
postpartum haemorrhage (1.5-2L blood loss) can contribute to the identification 
of women that may benefit from targeted haemostatic treatment (chapter 3). 
- The administration of larger volumes of clear fluids is associated with more 
severe deterioration of coagulation parameters corresponding to dilution, which 
is most pronounced during the earlier phases of postpartum haemorrhage 
(chapter 4). 
- Comparability between ROTEM® parameters from the Delta and Sigma device 
varies per assay. The early FIBTEM assays in particular should be interpreted with 
caution (chapter 5).
- The optimal cut-off point to detect women with a low fibrinogen concentration 
(≤2 g/L) was identified at a FIBTEM A5 value of 12mm. By using this cut-off, 87 
percent of women who need fibrinogen (Clauss fibrinogen concentration ≤2 
g/L) will be treated.  Downside is that a large majority of women (81%) will be 
treated with fibrinogen concentrate, although these women in fact have high 
fibrinogen concentrations (chapter 6)
- In a high-resource setting, the effect of administration of tranexamic acid during 
postpartum haemorrhage on both blood loss and the combined endpoint of 
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Prediction prior to childbirth
Major obstetric haemorrhage during pregnancy, childbirth and puerperium continues to 
be an important health problem around the world. In low-resource countries, it remains 
the leading cause of maternal mortality, whereas in high-resource countries it accounts 
for almost half of all severe acute maternal morbidity1-4. Despite improvements initiated 
by the worldwide implementation of postpartum haemorrhage protocols, recent studies 
suggest a steady increase of postpartum haemorrhage in high-resource countries, which 
can only be partially explained by an increase in maternal age, multiple pregnancies 
and caesarean sections ratesCanada, 2001-2009.\n\nPOPULATION: All women with 
live births or stillbirths.\n\nMETHODS: Detailed clinical information was obtained for 
371\u00a0193 women from the British Columbia Perinatal Data Registry. Outcomes of 
interest were atonic PPH and severe atonic PPH (atonic PPH with blood transfusion \
u22651 unit; atonic PPH with blood transfusion \u22653 units or procedures to control 
bleeding4-11. Although risk factors are often known to be present during pregnancy 
and birth, postpartum haemorrhage frequently occurs unexpectedly12-14. Also, women 
with known risk factors for postpartum haemorrhage often do not bleed excessively 
following childbirth. It has therefore proven difficult to develop a reliable prediction 
model for postpartum haemorrhage based on clinical risk factors12, 15, 16. From studies on 
von Willebrand disease it is known that the best results for prior assessment of bleeding 
risk come from more structured approaches to history taking by means of bleeding 
assessment tools (BATs)17-19. The TeMpOH-2 study was the first study to examine the value 
of a bleeding score acquired during pregnancy as a screening tool for the identification 
of women with an increased risk of excessive blood loss postpartum. An already existing 
and validated bleeding assessment tool (the condensed MCMDM-1VWD) was adjusted to 
a written questionnaire that could be used as a self-assessment bleeding score. Medical 
terminology was converted into lay language and detail was added to items that needed 
additional explanation or examples that would otherwise be given by an expert18. In the 
1147 pregnant women in the TeMpOH-2 study who completed a bleeding assessment 
tool during pregnancy, the ability of the score to discriminate between women with and 
without postpartum haemorrhage was found to be poor. This finding did not come as 
an utter surprise, since in the area of von Willebrand disease, bleeding scores are used 
because of their high negative predictive value, indicating that a normal bleeding score 
can help exclude a clinically significant bleeding disorder20. In line with this, in a study of 
217 individuals screened for von Willebrand disease, seventeen individuals with negative 
bleeding scores underwent major surgery, and none experienced significant bleeding. 
In another study in a cohort of paediatric patients undergoing adenotonsillectomy, an 
abnormal bleeding score without the addition of a coagulation screen did not have any 
predictive value for the occurrence of post-surgery haemorrhage21. No previous studies 
were found that examined the predictive value of the use of bleeding scores in the field of 
childbirth. In the TeMpOH-2 study no evidence was found to support adding a bleeding 
assessment tool to the review of a pregnant woman’s medical history for the prediction 
of postpartum haemorrhage of ≥ 1000mL. However, adding two questions on history 
of nosebleeds and post-surgery blood loss to a standard anamnesis did contribute to 
the identification of women with a higher risk of postpartum haemorrhage exceeding 
2000mL. The downside of this approach is that, looking at its relatively low positive 
predictive value (11%), this approach would in many cases be false alarm leading to 
unnecessary preventive measures.
 
Prediction and diagnosis during early postpartum haemorrhage 
Since a bleeding score prior to childbirth was not found to be useful in the prediction 
of postpartum haemorrhage, another potential predictor to look into was coagulopathy 
occurring during postpartum haemorrhage. From earlier studies into coagulopathy 
developing during postpartum haemorrhage several important methodological 
challenges had become apparent: identifying whether the observed change in a 
coagulation parameter is a predictor or rather the result of postpartum haemorrhage, 
asking for informed consent in an acute clinical setting, and last but not least selection of 
the appropriate target population. 
By close monitoring of haemostasis, abnormalities in coagulation parameters may be 
detected soon after their onset. This could contribute to more individually targeted 
haemostatic therapy for women experiencing postpartum haemorrhage, potentially 
leading to better maternal outcomes22. Previous studies have suggested that a low 
fibrinogen concentration might be the earliest predictor of progression towards severe 
postpartum haemorrhage23-26. A review article summarizing results of five studies 
concluded that a fibrinogen concentration of ≤ 3 g/L and, in particular ≤2 g/L was 
associated with progression towards more severe postpartum haemorrhage26. These 
studies had several drawbacks: either the volume of blood loss at blood sampling was not 
known, or only first and worst values of levels of coagulation parameters were reported. 
Therefore, it has remained unclear whether an observed change in concentration of a 
coagulation parameter is the result of bleeding or a predictor of progression towards 
more severe bleeding. Also, most studies had a prospective design, leading to challenges 
related to obtaining informed consent from women with severe bleeding and undertaking 
trial procedures whilst treating them. Because of these challenges, the most severe cases 





GENERAL DISCUSSION AND SUMMARY
The unique strength of the retrospective design of the TeMpOH-1 study was that it enabled 
us to include all women with severe postpartum haemorrhage from 61 participating 
hospitals during the study period, including the most severe cases. This allowed for 
reliable and generalizable estimation of proportions of women with coagulopathy 
during the course of postpartum haemorrhage. In the women of the TeMpOH-1 study 
cohort, we mapped patterns of change in coagulation parameters in relation to the 
phases of postpartum haemorrhage and were able to identify timing of these changes 
associated with risk of severe maternal outcomes. This enabled us to distinguish between 
a change in coagulation parameter concentration as a predictor of excessive bleeding 
versus a change as a result of volume of blood loss. Included were 1312 women who 
experienced severe postpartum haemorrhage and had at least one valid measurement 
of coagulation parameters sampled during active bleeding. We have elucidated that 
women who experienced postpartum haemorrhage without developing a composite 
outcome of maternal morbidity and mortality only sporadically reached a fibrinogen 
value of ≤2 g/L (blood loss above 3.5 litres). Women who did develop the composite 
adverse outcome reached such low fibrinogen levels much earlier (1.5-2L of blood loss) 
during postpartum haemorrhage. A similar pattern was observed for aPTT levels. This 
difference in the moment of reaching a level of fibrinogen of ≤2 g/L during the course of 
postpartum haemorrhage is essential for the selection of the target population for future 
studies into the potential benefit of administering fibrinogen concentrate. The results of 
the TeMpOH-1 study confirm the results of previous studies into this subject, but with 
one very important addition for acute clinical decision-making: the dimension of time. 
In our cohort, we observed higher occurrence of fibrinogen concentrations below 2 g/L 
compared to results suggested in previous prospective studies27, 28. This confirms the 
unique strength of our retrospective study and once more emphasizes the challenges 
for (future) prospective studies into potential treatment effects of fibrinogen concentrate, 
as previously experienced by research groups in Denmark and the UK: both groups had 
trouble selecting the appropriate target population (few women had fibrinogen levels ≤ 2 
g/L) for their intervention (fibrinogen concentrate versus placebo in women experiencing 
postpartum haemorrhage) and both were therefore unable to draw conclusions on 
treatment effect of fibrinogen concentrate27, 28.   
The TeMpOH-1 cohort also allowed for a description of changes in coagulation 
parameters after applying different fluid management strategies during various phases 
of severe postpartum haemorrhage. No previous studies described this association in 
women experiencing haemorrhage. International guidelines on management of women 
with severe postpartum haemorrhage highlight the lack of evidence on the effect of 
different fluid management strategies. In our cohort of women experiencing postpartum 
haemorrhage, changes were displayed in coagulation parameters after administering 
different volumes of fluids. Administration of larger volumes of clear fluids was associated 
with more severe worsening of levels of haemoglobin, haematocrit, platelet count, 
fibrinogen, aPTT and PT, which was most pronounced during the earlier phases of 
haemorrhage. These findings corroborate results of previous in vitro studies into the effect 
of dilution on coagulation parameters, where PT and aPTT were significantly prolonged 
after 60% and 80% dilution and levels of dilution-dependent coagulation factors and 
aPTT were found to decrease in an almost linear manner reaching critically low levels of 
coagulation parameters at dilutions of between 60% and 75%29, 30. Our findings provide 
evidence to reinforce expert opinion-based guidelines recommending restrictive fluid 
resuscitation strategies in case of postpartum haemorrhage; when clinical conditions 
allow for it, administration of large volumes of clear fluids should be avoided, because of 
their deteriorating impact on coagulation parameter levels.
From these studies in women of the TeMpOH-1 cohort, we have learned that timely 
detection of changes in levels of relevant coagulation parameters could play an essential 
role in the management of postpartum haemorrhage. From previous studies, a low 
fibrinogen concentration emerges as the earliest predictor of progression towards severe 
postpartum haemorrhage23, 24,26, 31-33. By timely detection of low fibrinogen concentrations, 
targeted haemostatic therapy may be administered to restore adequate concentrations 
of fibrinogen. The Clauss fibrinogen assay is the standard coagulation test to assess 
fibrinogen concentrations. Its downside is a turn-around time of up to 60 minutes, 
rendering it unsuitable for acute clinical decision making34. Point-of-care devices like 
ROTEM® thromboelastometry can detect changes in the coagulation system within ten 
minutes from blood sampling22. Evidence on correlation between fibrinogen concentration 
measured by the Clauss fibrinogen assay and the ROTEM® equivalent FIBTEM® and stability 
of the measurements in women experiencing postpartum haemorrhage was limited35, 36. 
Several studies conducted in women during postpartum haemorrhage have confirmed 
that the ROTEM® FIBTEM A5 assay, available 7 to 10 minutes after sampling, provides 
an indication of the fibrinogen concentration during postpartum haemorrhage22, 25, 37. 
In contrast with the evidence-based consensus on the Clauss fibrinogen concentration 
of ≤ 2 g/L as predictor of adverse outcome, this level of agreement is lacking for the 
corresponding ROTEM® FIBTEM A5 cut-off value. From a literature search we learned 
that several (research) groups working with thromboelastometry composed their own 
treatment flowcharts containing various FIBTEM cut-off points to initiate administration 
of fibrinogen concentrate. These flowcharts are often based on expert opinion rather than 
data28, 38. As discussed earlier, one of the problems that will occur while investigating an 
intervention in the wrong target population, is the impossibility to draw valid conclusions 
on the added value of the intervention. Once more, this expresses the importance of 
assessing the correct level of ROTEM® FIBTEM corresponding to women with fibrinogen 
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Another important topic while working with laboratory devices is the introduction of a 
new version of a device. Until recently, the ROTEM® Delta device was the most common 
device to conduct thromboelastometry. Now, a fully automated successor of the ROTEM® 
Delta device, the Sigma was introduced. The fact that with this device there is no need for 
a pipetting procedure, makes it more applicable as a point-of-care device to be used at 
bedside. When a successor of a device is launched onto the market it is of great clinical 
importance to perform validations to review whether the newly introduced device 
provides exactly the same values as its predecessor. Because ROTEM® values within the 
millimetre of accuracy are commonly used in (postpartum) haemorrhage treatment 
flowcharts, excellent correlation between values from the old and new device is extremely 
important.
Therefore, we conducted a prospective multicentre study, TeMpOH-2, comprising a 
large cohort of unselected pregnant women and following them until discharge from 
hospital after childbirth. To overcome issues concerning the informed consent procedure 
whilst treating women in an acute situation, consent had already been obtained during 
pregnancy or could be obtained verbally during early postpartum haemorrhage.  In women 
experiencing blood loss exceeding 800mL, repeated blood sampling was performed 
with a maximum of three samples, comprising traditional coagulation parameters and 
ROTEM® assays.  First, a sub-study was performed to compare values provided by the two 
ROTEM® devices, Delta and Sigma. In the cohort of 23 women experiencing postpartum 
haemorrhage, a strong positive correlation was displayed between thromboelastometry 
assays EXTEM, INTEM and APTEM executed on the ROTEM® Delta and Sigma device: 
results of these assays from both devices are similar. Clotting time (CT) values as obtained 
by the Sigma device were unreliable. Wide variation was shown between ROTEM® FIBTEM 
assays performed on both devices, especially in the earlier measurements (A5 and A10), 
important to acute clinical decision-making. No other studies have been published on 
this subject, making this a very important message for the ROTEM user community. Given 
the fact that exact FIBTEM A5 values are used in (postpartum haemorrhage) flowcharts 
around the world, we advise to re-evaluate the values used in a treatment flowchart when 
switching to the new device.
Subsequently, we assessed the optimal ROTEM® FIBTEM A5 value for detecting women 
with a Clauss fibrinogen concentration ≤2 g/L in our TeMpOH-2 cohort. Over the three-year 
inclusion period, 17203 women gave birth in the participating hospitals. Of these women, 
1605 experienced postpartum haemorrhage and 591 women agreed to participate in 
the study. For 511 women valid corresponding measurements of fibrinogen and FIBTEM 
A5 were available resulting in 637 samples. When comparing ROTEM® FIBTEM A5 results 
to Clauss fibrinogen levels, we found a moderate Spearman’s correlation coefficient of 
0.64 (95% Confidence Interval (CI): 0.60 to 0.69). Spearman’s correlation coefficients for 
measurements on the ROTEM® Delta and Sigma device were (rs) 0.63 (95% CI: 0.58 to 0.67) 
and (rs) 0.76 (95% CI: 0.63 to 0.85) respectively. These results corroborate results of a previous 
study in women experiencing postpartum haemorrhage, where a similar correlation was 
found25. The choice for a cut-off point for a diagnostic test depends on the risk of adverse 
outcomes when patients are incorrectly classified and/or incorrectly treated. Since the 
risk of adverse outcomes was found to be very high when fibrinogen concentrations are 
below 2 g/L, sensitivity of the test to detect women with fibrinogen below 2 g/L should 
be high. Our most important aim was to describe fibrinogen concentrations according to 
previously proposed FIBTEM A5 cut-off points in blood samples collected from women 
suffering postpartum haemorrhage since there was no consensus on the optimal cut-off 
point for FIBTEM A5 and results of previous studies lacked conformity in their conclusions. 
In a previous trial comparing administration of fibrinogen concentrate to placebo in 
women with postpartum haemorrhage, a cut-off of 15 mm was used and no difference 
observed between groups with regard to number of units of red blood cells, plasma, 
cryoprecipitate and platelets transfused28. An earlier study in women with postpartum 
haemorrhage suggested a FIBTEM A5 value of 6 mm as the cut-off point that correlates 
best with a Clauss fibrinogen ≤2 g/L (sensitivity 100%, specificity 87%).   
In the TeMpOH-2 cohort, the ability of FIBTEM A5 to discriminate observations with a 
Clauss fibrinogen concentration of ≤2 g/L was good, area under Receiver Operating Curve 
0.92 (95% confidence interval (CI) 0.87 to 0.97). The best cut-off point in the TeMpOH-2 
cohort was 12mm with sensitivity of 87% and specificity of 81%, missing 4 of 31 cases 
(13%) of Clauss fibrinogen ≤2 g/L and incorrectly selecting 118 (81%) (Table 3). When 15 
mm was applied as FIBTEM A5 cut-off point, 97% (30/31) of samples with Clauss fibrinogen 
≤2 g/L were accurately selected, but 89% (248/278) of selected samples had fibrinogen 
concentrations >2 g/L. When a lower cut-off value for FIBTEM A5 was chosen, these 
numbers changed: a cut-off value of FIBTEM A5 of 6 mm accurately selected 26% (8/31) 
of samples with Clauss fibrinogen concentrations ≤2 g/L and 74% (23/31) of samples with 
a low fibrinogen were missed. Yet, a lower percentage of 53% (9/17) of samples that were 
selected based on FIBTEM A5 value < 7 mm had corresponding Clauss fibrinogen values 
of >2g/L. 
Since FIBTEM A5 has been promoted to diagnose fibrinogen deficiency and guide 
treatment with fibrinogen concentrate and assuming that women suffering postpartum 
haemorrhage with Clauss fibrinogen concentrations ≤2 g/L require administration of 
fibrinogen concentrate, we conclude that FIBTEM A5 is useful but lacks specificity. Using 
FIBTEM A5 with a cut-off point of 12 mm will lead to a large number of women receiving 
fibrinogen concentrate in vain. The development of a point-of-care test that truly measures 
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Treatment options during persistent postpartum haemorrhage 
When the situation occurs that postpartum haemorrhage does develop, despite all 
prognostic and preventive measures, time has come to focus on interventions with 
haemostatic agents39, 40. One of these is tranexamic acid, an antifibrinolytic agent inhibiting 
dissolution of the fibrin clot by binding to plasminogen and blocking the interaction of 
plasmin(ogen) with fibrin 41. Tranexamic acid has been shown to reduce blood loss and 
need for blood transfusion in both elective and emergency surgery42. Blood loss after 
caesarean and vaginal births was also found to be somewhat reduced by administration 
of tranexamic acid in absence of significant maternal and neonatal complications43. In 
severely bleeding trauma patients, tranexamic acid was found to reduce mortality by 10-
15% 44.  The WOMAN trial, which compared tranexamic acid in an early stage of postpartum 
haemorrhage to placebo, showed a reduction of maternal mortality due to bleeding from 
1.9% to 1.5%. However, this trial was conducted primarily in low-resource settings and 
no differences were found in all-cause mortality or other clinical endpoints concerning 
maternal morbidity. Also, the effect of tranexamic acid on volume of blood loss was not 
studied. Since maternal mortality has become a rare event in high-resource countries, it 
remains unclear whether administration of tranexamic acid at an early stage in the course 
of postpartum haemorrhage has a positive effect on clinical outcome or volume of blood 
loss in a high-resource setting.
In the TeMpOH-1 cohort we quantified the association between tranexamic acid 
administration at an early stage in the course of persistent postpartum haemorrhage and 
severe acute maternal morbidity and blood loss in a high-resource setting. Women not 
responding to first line therapy were considered to suffer from persistent postpartum 
haemorrhage. In a cohort of 1260 women we found no difference or a clinically irrelevant 
reduction in blood loss in women who were treated with tranexamic acid early during 
persistent postpartum haemorrhage. Also, early treatment with tranexamic acid during 
persistent postpartum haemorrhage did not demonstrate a significant favourable effect 
on the frequency of composite acute maternal morbidity and mortality. 
Previous studies focused on the use of tranexamic acid for prevention of postpartum 
haemorrhage, rather than treatment of postpartum haemorrhage40. Our results 
corroborate the findings of these studies. A systematic review and meta-analysis of 
RCTs that studied the effect of the prophylactic use of tranexamic acid for postpartum 
haemorrhage, showed a similar reduction in mean blood loss of 149 ml45. So far, few 
studies have looked at the effect of tranexamic acid on maternal outcome in the treatment 
of postpartum haemorrhage. The most important one is the already mentioned WOMAN 
trial, in which 20 060 women from mostly low-resource settings with blood loss above 
500 ml were included. A reduction in maternal death due to bleeding from 1.9% to 1.5% 
was found. The largest effect occurred in the group of patients that received tranexamic 
acid within 1-3 hours after birth. Surprisingly, no difference was found with regard to 
(severe) maternal morbidity. Since maternal mortality is rare in a high resource setting, 
the treatment effect on mortality as found in the WOMAN trial is expected to be negligible 
when translated to our study population.  Based on our results and the promising results 
of early tranexamic acid treatment in trauma medicine and elective and acute surgery and 
the results of the WOMAN trial, its good safety profile (when administered in dosages of 
15mg/kg) and the fact that tranexamic acid is inexpensive, there seem to be few reasons 
not to administer tranexamic acid early during the course of persistent postpartum 
haemorrhage, yet the effect on clinical endpoints may be limited or absent42, 44. 
 
Strengths and limitations
The unique strength of the retrospective design of the TeMpOH-1 study was that it enabled 
us to include all women with severe postpartum haemorrhage from the 61 participating 
hospitals during the study period, including the most severe cases. This allowed for 
reliable and generalizable estimation of proportions of women with coagulopathy during 
the course of postpartum haemorrhage. When looking at limitations of the studies in 
this thesis, for both the TeMpOH-1 and TeMpOH-2 cohort the main limitation is selection 
bias. TeMpOH-1 included women who received at least four units of red cells or any 
transfusion of fresh frozen plasma (FFP) and/or platelets in addition to red cells because 
of obstetric haemorrhage (≥1000 mL blood loss during pregnancy, birth or puerperium). 
Results of the studies in the TeMpOH-1 cohort are thus derived from women suffering 
from severe postpartum haemorrhage necessitating blood transfusion. This should be 
taken into account while interpreting the results and applying these to other settings. 
Besides the fact that the retrospective design enabled us to study the most severe cases 
of haemorrhage, this design also has limitations: we did not have control over the number 
and specific panels of coagulation samples. Therefore, our results are based on different 
selections of women in the categories of blood loss.  
Two out of three hospitals participating in the TeMpOH-2 study were university hospitals. 
This may have led to selection bias because of a difference in source population. Although 
we were able to include a large cohort of pregnant women with a broad range of gestational 
ages and pregnancy risk-profiles the high incidence of postpartum haemorrhage shows 
that our study population comprises a relatively high number of women with a high risk 
of postpartum haemorrhage. Also, additional counselling to obtain informed consent was 
performed during admissions preceding elective caesarean sections, potentially leading 
to overrepresentation of women who underwent caesarean section. In studies comparing 
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study on the predictive value of bleeding scores, the presence of selection bias is obvious 
from the relatively high incidence of women suffering from postpartum haemorrhage 
as opposed to the general population. Yet, if anything, a higher incidence might have 
influenced the predictive value of the questionnaire in a positive way. We therefore infer 
that the poor predictive value of our questionnaire is not the result of selection bias.
Future perspectives
When confronted with women who develop postpartum haemorrhage, obviously the 
first actions to be taken are measures leading to cessation of bleeding. 
Whilst treating acutely bleeding women, several important questions 
will spring to the mind of caregivers: is this woman going to continue 
bleeding? Will she develop more severe postpartum haemorrhage 
with a subsequent adverse outcome? What can I do to prevent her 
from reaching these severe stages of postpartum haemorrhage? 
An answer to these questions can be provided by diagnostic and 
prognostic tests. These diagnostic and prognostic tests support 
caregivers in their capacity to distinguish between postpartum 
haemorrhages with and without an increased risk of subsequent 
adverse maternal outcome. 
From the results as described in this thesis we have learned that 
a bleeding assessment tool providing a bleeding score does not 
contribute to prediction of postpartum haemorrhage whereas 
history of postpartum haemorrhage does. Monitoring coagulation 
was shown to be a relevant diagnostic test that could serve as a useful 
application in the prediction of development of severe postpartum 
haemorrhage, when taken into account one important addendum: 
the essence of the difference in the moment of reaching a level of 
fibrinogen of ≤2 g/L during the course of postpartum haemorrhage. 
Thus, a great deal of opportunities exist in the field of close monitoring 
of coagulation. Quick yet stable and reliable tests to establish levels 
of coagulation parameters are necessary to cope with the challenges 
of acutely bleeding women. Also, the effects of targeted haemostatic 
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Until now, it remains unclear whether implementation of thromboelastometry in 
peripartum care, indeed does lead to better maternal outcomes. Future studies should focus 
on evaluation of the added value of implementation of thromboelastometry as standard 
care at the maternity ward.  Thromboelastometry provides a faster indication of a patient’s 
coagulation status compared to traditional coagulation testing methods. It could provide 
close monitoring of haemostasis by detecting abnormalities in coagulation parameters 
soon after onset. However, in contrast with traditional coagulation tests providing exact 
levels of coagulation parameters, thromboelastometry provides ‘qualitative assessments 
of clot formation and fibrinogen status’. Notably, these two results are not the same 
and cannot be used and interpreted interchangeably. Before implementation into daily 
clinical practice, thorough evaluation is necessary to determine whether values provided 
by thromboelastometry correspond to their traditional counterparts. In this thesis, we 
have determined these ROTEM® FIBTEM cut-off values for corresponding levels of Clauss 
fibrinogen in women experiencing postpartum haemorrhage. The next step before 
decisions can be made upon their incorporation in postpartum haemorrhage treatment 
flow-charts, is to establish their predictive value. For Clauss fibrinogen, it is already known 
that a level of ≤2 g/L serves as predictor for adverse maternal outcome. This level has yet 
to be determined for FIBTEM. Moreover, from our studies in the TeMpOH-1 and TeMpOH-2 
cohort we have learned, that the incidence of a fibrinogen concentration ≤2 g/L in women 
giving birth in the Netherlands is rather low: 0.18%. This once more emphasises the 
need for a reliable, quick, yet inexpensive test, since many women have to be tested to 
accurately select the ones in actual need of treatment with fibrinogen concentrate.
Moreover, a very important action to be taken is the evaluation of the association 
between the implementation of thromboelastometry in clinical practice and maternal 
outcomes of postpartum haemorrhage. A distinction that has to be made during this 
evaluation, is whether an observed (positive or negative) effect on maternal outcome did 
occur because of the use of thromboelastometry or as a result of the commissioning of a 
strict postpartum haemorrhage treatment protocol. Given the difficulties of randomising 
women during an acute situation like postpartum haemorrhage, in particular the most 
severe cases, choice of an appropriate study design is of utmost importance. A way to 
study this in an epidemiologically sound manner without the challenges of undertaking 
study procedures in an acute situation would be to perform a trial using a stepped 
wedge design. In the first phase of the study a postpartum haemorrhage protocol with 
haemostatic interventions at set times will have to be implemented in maternity wards 
that have not yet been exposed to thromboelastometry. In the second phase of the study, 
these hospitals will get the availability of a ROTEM® device, and now the interventions of 
the postpartum haemorrhage protocol will be based on the set ROTEM® cut-off values. 
This study design enables reliable assessment of the added value of thromboelastometry 
to standard postpartum haemorrhage care as to maternal outcomes and amount of 
blood products transfused. Based on our experiences with thromboelastometry in the 
TeMpOH-2 study, this trial is a necessary step to be taken before implementation of 
thromboelastometry in standard postpartum haemorrhage care protocols. 
Coming to the end of this theses we can conclude that the results have provided many 
answers, but also led to new questions: is there a future for thromboelastometry in 
peripartum care? That answer seems easy: thromboelastometry is not likely to ever become 
an indispensable part of postpartum haemorrhage care, if only for the fact that it will 
never become available for a large part of the clinics providing maternity care worldwide, 
because of its high price and need for continuous technical support and monitoring. When 
looking into the technique that is used in thromboelastometry one could wonder to what 
extent the ‘qualitative assessment of clot formation’ by thromboelastometry differs from 
the visual inspection of clot formation that can be performed by collecting blood in a 
non-citrated tube and wait to see what happens. Obviously, visual inspection does not 
provide an estimation of a woman’s fibrinogen concentration. However, we have learned 
from the studies in this thesis, that FIBTEM A5 also seems to lack specificity in providing 
a correct estimation. Yet, FIBTEM A5 has proven to be useful as a more general indicator 
of coagulation capacity in a cohort of women experiencing postpartum haemorrhage, 
leading to reduction of FFP use46. For more accurate estimations of a woman’s fibrinogen 
concentration, in case treatment with fibrinogen concentrate is considered, a fast and 
stable fibrinogen assay could serve as a useful addition to visual inspection of clot 
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Postpartum haemorrhage, in this thesis defined as blood loss above 1000mL within the 
first 24 hours after birth, remains a major cause of maternal morbidity and mortality 
with an incidence that seems to be increasing over the last decade1-8. In this thesis we 
focussed on improvement of prognostic and diagnostic strategies for major obstetric 
haemorrhage, which may subsequently lead to a reduction of severe maternal morbidity, 
mortality and need for surgical interventions. In pursuit of this aim, research questions 
were posed corresponding to all three phases leading up to adverse outcome due to 
postpartum haemorrhage: pregnancy (prior to childbirth), early postpartum haemorrhage 
and persistent postpartum haemorrhage. In the first part of this thesis we focused on 
prediction of postpartum haemorrhage
In Chapter 2 we prospectively evaluated the predictive value of a bleeding assessment 
tool for postpartum haemorrhage.  In our cohort of 1147 women, the ability of the 
bleeding score to contribute to the discrimination between women with and without 
postpartum haemorrhage was poor. The most important reasons for this negative result 
were a high negative predictive value of the bleeding score, and obstetrical factors as 
main primary causes of postpartum haemorrhage. Hence, no evidence was found to 
support adding a bleeding assessment tool to the review of a pregnant woman’s medical 
history for the prediction of postpartum hemorrhages of ≥1000 mL. However, adding two 
questions on medical history of nosebleeds and post-surgery blood loss to a standard 
anamnesis could enable a clinician to identify women with a higher risk of postpartum 
hemorrhage exceeding 2000 mL. Clinicians should contemplate whether they find this of 
clinical significance for individual patients.
In Chapter 3 coagulation parameters during the course of severe postpartum 
haemorrhage were described, comparing coagulation parameters during early postpartum 
haemorrhage between women with and without adverse maternal outcome. Our findings 
demonstrate that detection of low levels of fibrinogen and elevated aPTT levels during 
early postpartum hemorrhage can contribute to the identification of women that may 
benefit from targeted hemostatic treatment. Essential in this identification process is 
the moment of reaching a level of fibrinogen of ≤2g/L during the course of postpartum 
hemorrhage. Based on these results we advise to assess levels of fibrinogen and aPTT in 
all women who experience postpartum hemorrhage with blood loss exceeding 1000mL. 
In the second part of the thesis we focused on improvement of diagnostic strategies for 
postpartum haemorrhage. In Chapter 4 changes in levels of coagulation parameters 
after administration of different volumes of clear fluids to women suffering from major 
postpartum haemorrhage were described. Administration of larger volumes of clear 
fluids was associated with more severe worsening of levels of haemoglobin, haematocrit, 
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platelet count, fibrinogen, aPTT and PT which was most pronounced during the earlier 
phases of postpartum haemorrhage. Our findings provide quantitative evidence to 
reinforce expert opinion-based guidelines recommending restrictive fluid resuscitation 
strategies in case of postpartum haemorrhage. 
By the timely detection of changes in levels of relevant coagulation parameters, targeted 
hemostatic therapy to restore deficiencies could be administered. However, assessment 
of fibrinogen levels by a standard coagulation test like the Clauss fibrinogen assay has 
a turn-around time of up to 60 minutes making it unsuitable for acute clinical decision 
making20. Point-of-care devices like ROTEM® thromboelastometry are able to detect 
essential changes in the coagulation system within 10 minutes after blood sampling21. 
During the course of the TeMpOH-2 study, the ROTEM® Sigma was introduced, a fully 
automated successor of the ROTEM® Delta device. 
In Chapter 5 we compared ROTEM® parameters using the ROTEM Delta and Sigma devices 
in women experiencing postpartum haemorrhage to determine whether these devices 
provided similar results. We found that results from ROTEM® FIBTEM assays of the devices 
differed significantly, especially in the earlier measurements (A5 and A10) emphasizing the 
need to validate new devices before implementation and obtain device specific reference 
ranges, to inform appropriate device specific intervention points on an algorithm. 
FIBTEM A5 has been promoted as the ROTEM equivalent to the Clauss fibrinogen assay 
which could be used to diagnose fibrinogen deficiency and guide treatment with 
fibrinogen concentrate. 
In Chapter 6  fibrinogen concentrations were described according to previously proposed 
FIBTEM A5 cut-off points in blood samples collected from women suffering postpartum 
haemorrhage. Our findings suggest that the best cut-off point to accurately select women 
with a Clauss fibrinogen concentration of ≤2 g/L in our cohort was a FIBTEM A5 value of 
12mm. When this cut-off was applied, 87 percent of women in need of fibrinogen were 
treated.  Downside is that a large majority of women (81%) was treated with fibrinogen 
concentrate, although they in fact had high fibrinogen concentrations. The development 
of a point-of-care test that really measures fibrinogen concentration could be of 
considerable clinical significance. 
The last part of this thesis focussed on haemostatic treatment in case of persistent 
postpartum haemorrhage. In Chapter 7 the association between tranexamic acid 
administration at an early stage in the course of persistent postpartum haemorrhage and 
severe acute maternal morbidity and blood loss in a high-resource setting was quantified. 
Our findings suggest that in a high-resource setting, the effect of administration of 





endpoint of maternal mortality and morbidity may be disappointing. Judging from the 
promising results of early tranexamic acid treatment in trauma medicine and elective 
and acute surgery and the results of the WOMAN trial, its good safety profile (when 
administered in dosages of 15mg/kg) and the fact that tranexamic acid is inexpensive, 
there seem to be few reasons not to administer tranexamic acid early during the course 
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Fluxus postpartum, in dit proefschrift gedefinieerd als een hoeveelheid bloedverlies van 
tenminste 1000 ml binnen de eerste 24 uur na de bevalling, blijft één van de belangrijkste 
oorzaken van maternale morbiditeit en mortaliteit wereldwijd, waarbij er ook nog steeds 
sprake lijkt te zijn van een toenemende incidentie. De focus van dit proefschrift ligt op het 
verbeteren van prognostische en diagnostische strategieën rondom fluxus postpartum, 
met als overkoepelend doel het bewerkstelligen van een reductie van ernstige maternale 
morbiditeit, mortaliteit en noodzaak tot het doen van chirurgische interventies. Om dit 
doel te kunnen bereiken werden onderzoeksvragen opgesteld corresponderend met drie 
perioden rondom zwangerschap en geboorte waarin prognostische en diagnostische 
strategieën kunnen worden ingezet: (1) zwangerschap (de fase voorafgaand aan de 
geboorte), (2) de beginfase van fluxus postpartum en (3) persisterende fluxus postpartum.
Ad 1. Predictie tijdens zwangerschap: zijn er mogelijkheden om al tijdens de 
zwangerschap te voorspellen welke vrouwen een verhoogd risico hebben op fluxus 
postpartum?
Ad 2. Predictie en diagnose tijdens de beginfasen van fluxus postpartum: is het 
mogelijk om al in de beginfase van fluxus postpartum vrouwen te identificeren, met 
een verhoogd risico op een ernstige afloop van fluxus postpartum? Maar ook, zijn er 
mogelijkheden om deze vrouwen op een snelle én betrouwbare manier te identificeren?
Ad 3. Behandelopties in het geval van persisterende fluxus postpartum: kunnen we 
vrouwen met persisterend bloedverlies tijdens fluxus postpartum adequaat behandelen 
met hemostatica om het bloedverlies een halt toe te roepen?
Om deze onderzoeksvragen te beantwoorden werden twee grote multicenter 
cohort studies opgezet. De Transfusion strategies in women during Major Obstetric 
Haemorrhage-1 (TeMpoH-1) studie was een nationale retrospectieve cohort studie 
in 61 ziekenhuizen in Nederland, waarin tussen 2011 en 2013 191.772 bevallingen zijn 
geëvalueerd. De TeMpOH-2 (Towards better Prognostic and Diagnostic strategies for 
Major Obstetric Haemorrhage) studie was een prospectief cohort onderzoek in drie 
ziekenhuizen in Nederland waarin tussen februari 2015 en april 2018 17.203 bevallingen 
zijn geanalyseerd. In totaal werden in beide studies 1982 vrouwen met (ernstige) fluxus 
postpartum geïncludeerd. Een deel van de resultaten van de TeMpOH-1 & 2 studies zijn 
beschreven in dit proefschrift. 
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In het eerste deel van dit proefschrift ligt de focus op predictie van fluxus postpartum. 
In hoofdstuk 2 presenteren we de prospectieve evaluatie van de voorspellende waarde 
van een bloedingsscore voor fluxus postpartum. Uit onderzoek is gebleken dat het 
inschatten van a priori bloedingsrisico in een subpopulatie met milde stollingsziekten 
zoals de ziekte van Von Willebrand het beste gedaan kan worden door gebruik te maken 
van gestructureerde anamnesevoering. Dit gebeurt door middel van een bleeding-
assessment tool (BAT) waarmee een bloedingsscore wordt gegenereerd. Wij hebben 
als eerste onderzocht of een tijdens de zwangerschap verkregen bloedingsscore kan 
bijdragen aan de identificatie van vrouwen met een verhoogd risico op het optreden van 
fluxus postpartum. In ons cohort van 1147 zwangere vrouwen, bleek het discriminerend 
vermogen van de bloedingsscore tussen vrouwen met en zonder uitkomst van fluxus 
postpartum slecht te zijn. De belangrijkste verklaringen voor dit negatieve resultaat waren 
de met name hoge negatief voorspellende waarde van de bloedingsscore en het feit dat 
verreweg de meeste gevallen van fluxus postpartum primair een obstetrische oorzaak 
hebben. Er werd dus geen bewijs gevonden dat het toevoegen van een gestructureerde 
anamnese op het gebied van bloedingssymptomen bijdraagt aan de identificatie van 
vrouwen met een verhoogd risico op fluxus postpartum. Uit ons onderzoek bleek wel 
dat het tijdens de zwangerschap positief beantwoorden van twee vragen t.a.v. frequent 
optreden van neusbloedingen en het hebben ervaren van een nabloeding na een 
eerdere chirurgische interventie een klein deel van de vrouwen (10%) met een fluxus 
postpartum >2000 ml op voorhand detecteerde. In de dagelijkse klinische praktijk zal de 
afweging gemaakt moeten worden, of dit klinisch relevant is voor het opstellen van een 
behandelplan voor een individuele patiënt. 
In hoofdstuk 3 presenteren we het beloop van stollingsfactoren over de tijd bij vrouwen 
die een ernstige fluxus postpartum hebben doorgemaakt. De hoeveelheid bloedverlies 
werd ingedeeld in categorieën, waarna de bloedafnames werden geanalyseerd in de 
categorie corresponderend met de hoeveelheid bloedverlies ten tijde van de bloedafname. 
Daarnaast werd een vergelijking gemaakt tussen de concentraties van stollingsfactoren 
gemeten tijdens vroege fluxus postpartum van vrouwen die mét en zonder gecombineerd 
eindpunt van ernstige maternale morbiditeit en mortaliteit eindigden. Onze bevindingen 
laten zien dat het meten van een laag Clauss fibrinogeengehalte (≤ 2g/L) of een verlengde 
APTT vroeg tijdens fluxus postpartum (1.5-2.0 L) kan bijdragen aan de identificatie van 
vrouwen met een verhoogde kans op een ernstig beloop van fluxus postpartum. Dit zijn de 
vrouwen die mogelijk baat hebben bij een geïndividualiseerde behandeling door middel 
van het gericht toedienen van hemostatica. Een fibrinogeen van ≤2g/L is in eerdere studies 
ook gevonden als voorspeller van een ernstiger beloop van fluxus postpartum. Essentieel 
in de bevindingen die wij presenteren is het moment waarop dit lage fibrinogeen gehalte 
bereikt wordt tijdens fluxus postpartum. Als een verlaagd fibrinogeen gehalte gemeten 





voorspeller van een slechtere maternale uitkomst van fluxus postpartum. Op basis van 
deze resultaten is ons advies om in geval van een persisterende fluxus postpartum bij een 
hoeveelheid bloedverlies van 1500ml een stollingsstatus te laten bepalen, waarbij in ieder 
geval fibrinogeen en APTT bepaald moeten worden. 
In het tweede gedeelte van dit proefschrift staat de verbetering van diagnostische 
methoden tijdens fluxus postpartum centraal. 
In hoofdstuk 4 beschrijven we de veranderingen optredend in concentraties van 
stollingsparameters als een gevolg van volumesuppletie door middel van kristalloïden 
en colloïden (clear fluids) tijdens fluxus postpartum.  Er werden drie categorieën gevormd 
(toediening van <2.0L, 2-3.5L en >3.5L helder vocht ten tijde van de bloedafname) 
op basis van adviezen ten aanzien van volumesuppletie tijdens fluxus postpartum 
door de Royal College of Obstetricians and Gynaecologists (RCOG). Concentraties van 
stollingsparameters werden ook in deze studie gecategoriseerd op basis van hoeveelheid 
bloedverlies op het moment van bloedafname. Een meer liberaal vochtbeleid (toediening 
van >2.0L ten tijde van de bloedafname) bleek geassocieerd te zijn met een duidelijke 
verslechtering van hemoglobine, hematocriet, trombocytengetal, fibrinogeen, aPTT en 
PT, waarbij de grootste veranderingen werden gezien tijdens de vroege fase van fluxus 
postpartum (bloedverlies 1-1.5L). Onze bevindingen bieden kwantitatief bewijs ter 
ondersteuning van de vooralsnog alleen op meningen van experts gebaseerde richtlijnen 
die een restrictief beleid t.a.v. volumesuppletie adviseren tijdens fluxus postpartum ter 
voorkoming van verdunningscoagulopathie. 
Door de vroegtijdige detectie van veranderingen van relevante stollingsparameters, kan 
doelgerichte behandeling met hemostatica worden toegepast om ontstane deficiënties 
in stollingsparameters aan te vullen. Een belangrijke factor daarbij is de tijd die het 
duurt tussen bloedafname en het uiteindelijke verkrijgen van het resultaat (turn-around 
time). Een standaard stollingstest, zoals bijvoorbeeld de Clauss fibrinogeen test, heeft 
een turn-around time van 60 minuten, waardoor deze test in de praktijk niet geschikt 
is om acute klinische beslissingen op te baseren. Stollings point-of care apparaten zoals 
ROTEM® waarbij er door middel van tromboelastometrie een kwalitatieve inschatting van 
de bloedstolling wordt verkregen, kunnen binnen 10 minuten essentiële veranderingen 
in de stollingsstatus detecteren. Ze worden dan ook in toenemende mate gebruikt bij 
cardiothoracale, lever- en traumachirurgie. In de verloskunde is de toegevoegde waarde 
van het gebruik van tromboelastometrie nog onduidelijk.  In de onderzoeken zoals 
beschreven in dit proefschrift werd het gebruik van tromboelastometrie tijdens fluxus 
postpartum onderzocht. Aangezien een Clauss fibrinogeengehalte ≤ 2g/L een voorspeller 
blijkt te zijn van een ernstige afloop van fluxus postpartum, ging onze interesse met name 
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uit naar het onderzoeken van de fibrinogeen equivalent van ROTEM®, die bekend is na 
7-10 minuten: FIBTEM A5.  
Tijdens het uitvoeren van deze studies werd de ROTEM® Sigma geïntroduceerd, de volledig 
geautomatiseerde opvolger van de eerder gebruikte ROTEM® Delta, waarbij er handmatig 
gepipetteerd diende te worden. In hoofdstuk 5 beschrijven we een vergelijking van 
ROTEM® parameters gemeten met de Delta en de Sigma bij vrouwen tijdens fluxus 
postpartum. Aangezien de Sigma werd geïntroduceerd als de opvolger van de Delta, was 
onze aanname dat de metingen die tegelijkertijd werden uitgevoerd op beide apparaten 
vergelijkbaar zouden zijn. In ons cohort bleek dat er significante verschillen waren tussen 
waarden voor FIBTEM  van beide apparaten. Het verschil bleek het grootst te zijn in de 
voor de kliniek meest relevante waarden met een uitslag die bekend is na 5 en na 10 
minuten, FIBTEM A5 en FIBTEM A 10. Onze bevindingen benadrukken de noodzaak om 
voorafgaand aan introductie en implementatie van een nieuw apparaat in de klinische 
praktijk, een validatieprocedure te doorlopen. Hierbij kunnen apparaat specifieke 
referentiewaarden worden vastgesteld, om te gebruiken in behandelalgoritmes.
Zoals eerder beschreven wordt ROTEM® FIBTEM A5 gezien als het snelle equivalent van 
Clauss fibrinogeen, om op een snelle manier een fibrinogeendeficiëntie vast te stellen en 
te gebruiken als een maat om toediening van fibrinogeenconcentraat te doseren. Het is 
in dit geval belangrijk om een maat te hebben waarmee zoveel mogelijk vrouwen met 
een daadwerkelijk laag fibrinogeen gehalte worden geïdentificeerd, zonder dat er aan de 
andere kant veel vrouwen fout-positief worden geselecteerd, terwijl ze in de praktijk een 
hoog genoeg fibrinogeen gehalte hebben.
In hoofdstuk 6 beschrijven we de associatie tussen Clauss fibrinogeen concentratie en 
ROTEM® FIBTEM A5 gemeten bij vrouwen tijdens fluxus postpartum. Daarnaast werden 
eerder beschreven afkappunten van FIBTEM A5 om vrouwen met een lage Clauss 
fibrinogeen concentratie (≤ 2g/L) te identificeren geanalyseerd. In ons cohort bleek een 
FIBTEM A5 waarde van 12mm het beste afkappunt te zijn om zoveel mogelijk vrouwen 
met een laag Clauss fibrinogeen gehalte te detecteren, met een sensitiviteit 87% van en 
een specificiteit van 81%. Als dit afkappunt wordt toegepast om vrouwen te selecteren 
met een laag fibrinogeen gehalte, waarbij er een noodzaak bestaat om fibrinogeen 
concentraat toe te dienen, wordt 87% van de vrouwen met een daadwerkelijk laag 
fibrinogeen geselecteerd. De keerzijde is, dat bij het hanteren van een afkapwaarde van 
FIBTEM A5 van 12 mm ook veel vrouwen worden geselecteerd die in de praktijk toch geen 
laag fibrinogeen blijken te hebben. Dit laatste is het geval voor 81% van de vrouwen. 
Dit betekent dat in ons cohort voor de heel gerichte toepassing van het identificeren 





FIBTEM A5 geen accurate meetmethode is gebleken. De ontwikkeling van een snelle én 
betrouwbare fibrinogeen point-of -care test is dan ook van groot klinisch belang.
Het laatste deel van dit proefschrift heeft als focus het toepassen van behandeling met 
hemostatica bij vrouwen met persisterende fluxus postpartum. 
In hoofdstuk 7 presenteren we de resultaten van ons onderzoek naar de associatie tussen 
het vroegtijdig toedienen van tranexaminezuur tijdens persisterende fluxus postpartum 
en het optreden van een gecombineerd eindpunt van ernstige maternale morbiditeit 
en mortaliteit in een setting met een hoog voorzieningen niveau. Persisterende fluxus 
postpartum werd gedefinieerd als persisterend bloedverlies ondanks het toepassen van 
eerstelijns maatregelen. Als voorbeeld werd bij een vastzittende placenta een manuele 
placentaverwijdering beschouwd als eerstelijns behandeling. Onze resultaten laten zien 
dat in deze setting de toegevoegde waarde van het vroeg toedienen van tranexaminezuur 
beperkt lijkt wat betreft vermindering van bloedverlies (min 177 ml). Daarnaast werd 
geen verschil gevonden in het optreden van het gecombineerde eindpunt van ernstige 
maternale morbiditeit en mortaliteit. Op basis van onze bevindingen, maar zeker ook 
kijkend naar de veelbelovende resultaten van de WOMAN trial, het goede veiligheidsprofiel 
van tranexaminezuur en de lage kostprijs, lijken er weinig redenen te zijn om geen 
tranexaminezuur toe te dienen vroeg tijdens fluxus postpartum. Kanttekening daarbij is 
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The Dutch Working Party ‘International Safe Motherhood and Reproductive Health’ aims to contribute to 
improvement of the reproductive health status of women around the globe, in particular by collaborating with 
local health workers (http://www.safemotherhood.nl). The Working Party is part of both the Dutch Society of 
Obstetrics and Gynaecology (NVOG) and the Dutch Society for International Health and Tropical Medicine 
(NVTG). The activities that are undertaken under the umbrella of the Working Party can be grouped into four 
pillars: education, patient care, research and advocacy. 
Research activities are undertaken by (medical) students, Medical Doctors International Health and Tropical 
Medicine and many others. Some research activities develop into PhD-trajectories. PhD- candidates all over the 
world, Dutch and non-Dutch, work on finding locally acceptable and achievable ways to improve the quality of 
maternal health services, supervised by different members of the Working Party. Professor Jos van Roosmalen 
initiated the Safe Motherhood Series, which started in 1995. 
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